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V Zusammenfassung 
Zusammenfassung 
 
Die chronische lymphatische Leukämie (CLL) ist eine der am häufigsten auftretenden 
Leukämieformen bei Erwachsenen in der westlichen Welt. Die Anreicherung von 
scheinbar ausgereiften B-Zellen im peripheren Blut, den lymphatischen Organen und dem 
Knochenmark ist charakteristisch für diese Krankheit. Obwohl die Applikation von neu 
entwickelten Medikamenten in den letzten Jahren zu einer Verbesserung des 
Krankheitsverlaufs der Patienten geführt hat, ist die CLL nach wie vor unheilbar. Daher ist 
die Entwicklung neuer Behandlungsstrategien von großer Bedeutung. 
Die CLL ist unter anderem eine Krankheit des Epigenoms, definiert durch genomweite 
Hypomethylierung und parallel auftretender Hypermethylierung in spezifischen Regionen. 
Hieraus resultiert die Deregulation von Tumorsuppressoren, nicht-kodierenden RNAs und 
Onkogenen. Die DNA Methylierung bleibt interessanterweise in der CLL über lange Zeit 
stabil. Gene die durch diese DNA Modifikation dereguliert werden könnten daher 
permanent beeinflusst sein, unabhängig vom Status und Verlauf der Krankheit. 
Das Ziel dieses Projektes war es, Gene zu identifizieren und zu charakterisieren, die in 
der CLL durch DNA Methylierung dereguliert sind und somit eine Rolle im 
Pathomechanismus der Krankheit spielen könnten. Zu diesem Zweck wurden mit Hilfe 
von Arrays Expressions- und Methylierungnsanalysen von CD19+ CLL Zellen und B-
Zellen gesunder Spender durchgeführt. Es konnte eine unterschiedliche Expression 
zwischen den Krebszellen und den normalen B-Zellen von 1866 Genen gezeigt werden. 
Von diesen wiesen 33 signifikant differentiell methylierte Regionen (DMR) auf, welche 
eine negative Korrelation zur Genexpression zeigten. Durch Quantifizierung der DNA 
Methylierung mit Hilfe von Massenspektrometrie konnten 17 dieser Gene validiert werden. 
Unter diesen befand sich auch der Stammzell- und Transkriptionsfaktor KLF4. 
Frühere Studien zeigen, dass KLF4 eine wichtige Rolle in der Differenzierung und Reifung 
von B-Zellen spielt und in anderen B-Zell Krankheiten als Tumorsuppressor agiert. Des 
Weiteren ist KLF4 ein Ziel-Gen von NOTCH1, welches in der CLL mutiert und konstitutiv 
aktiv ist. Tatsächlich, zeigte die Behandlung mit γ-sekretase Inhibitor von sechs 
verschiedenen lymphoblastoiden und leukämischen Zelllinien, sowie von mononukleären 
Zellen des peripheren Blutes (PBMCs) von 8 CLL Patienten, nicht nur eine Inhibition der 
NOTCH1 Aktivität in diesen Zellen, sondern auch eine Re-Expression von KLF4 sowohl 
auf RNA als auch auf Protein Ebene. Es kann somit eine transkriptionelle Regulation von 
KLF4 durch NOTCH1 angenommen werden. Überdies korrelierte die Expression von 
KLF4 in primären CLL- und B-Zellen mit den Mitgliedern der BCL-2 Proteinfamilie BAK, 
BAX und BCL-2, sowie mit dem Zellzyklus Regulator CCND1. 
Die transiente Überexpression von KLF4 in drei Leukämie Zelllinien führte zu einer 
Deregulation von Genen welche an BCR- und PI3K-Signaltransduktion beteiligt sind. 
Zusammenfassend deuten diese Ergebnisse darauf hin, dass die Repression von KLF4 
durch DNA Methylierung und NOTCH Signaltransduktion dazu beiträgt die CLL Zellen in 
einem hoch aktivierten Zustand zu halten, welcher die Expansion und das Überleben der 
malignen Zellen unterstützt. 
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VII Summary 
Summary 
 
Chronic lymphocytic leukemia (CLL) is one of the most common leukemias in adults in the 
Western world characterized by the accumulation of mature-appearing B-cells in the 
peripheral blood, lymphoid tissues and bone marrow. The use of novel inhibitors targeting 
BCR- and PI3K-signaling in CLL as well as the application of CD20-antibodies in the clinic 
have led to improved outcome for the patients. Nevertheless, CLL remains an incurable 
disease and in order to develop new treatment strategies, there is still a strong need to 
elucidate the pathomechanism of CLL further. 
CLL is amongst other aspects a disease of the epigenome, displaying genome-wide 
hypomethylation while specific regions are hypermethylated, resulting in the deregulation 
of tumor suppressors, non-coding RNAs and oncogenes. Interestingly, DNA methylation 
in CLL patients was shown to be relatively stable over time suggesting that genes which 
are deregulated by this DNA modification are affected permanently, independent of 
disease stage and course. 
In this project, it was therefore aimed to identify and characterize genes deregulated in 
CLL by DNA methylation, which are likely involved in the pathomechanism of the disease. 
To this end, expression and methylation array profiling was conducted in CD19+ sorted 
CLL cells and B-cells of healthy donors. Out of the 1,866 genes identified as differentially 
expressed between cancer cells and their non-malignant counterpart, 33 showed 
significantly differentially methylated regions (DMR) that displayed negative correlation 
with gene expression. Technical validation using mass spectrometry based quantification 
of methylation confirmed the presence of DMRs in 17 of these genes including the 
transcription and stem cell factor KLF4. 
KLF4, of which repression and hypermethylation could be confirmed in a larger patient 
subset, was previously shown to play an important role in B-cell differentiation and 
maturation and further to act as tumor suppressor in other B-cell malignancies including 
classical- and non-Hodgkin lymphoma. Moreover, KLF4 was shown to be a downstream 
target of NOTCH1 which is recurrently mutated and constitutively active in CLL.  
In fact, treatment of six different lymphoblastoid and leukemia cell lines and of primary 
peripheral blood mononuclear cells (PBMCs) from eight CLL patients with γ-secretase 
inhibitor resulted in the inhibition of NOTCH1 activity and in the re-expression of KLF4 on 
RNA and protein level, suggesting transcriptional regulation of KLF4 by NOTCH1. 
Furthermore, expression of KLF4 was correlated with levels of BCL-2 family members 
BAK, BAX and BCL-2 as well as the cell cycle regulator CCND1 in primary CLL and B-
cells. Although, overexpression of KLF4 in three leukemia cell lines did not induce 
apoptosis in these cells, it resulted in the deregulation of a number of genes involved in 
prominent signaling pathways which are highly relevant for the pathogenesis of CLL, 
including BCR- and PI3K-signaling.  
In summary, these findings suggest the repression of KLF4 by DNA promoter methylation 
and NOTCH signaling in CLL. Overexpression of KLF4 results in the deregulation of 
genes involved in signaling pathways important for B-cells which indicates that KLF4 is in 
part involved in keeping the CLL cells in a highly activated state. 
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2-HG 2-hydroxyglutarate 
5-CaC 5-carbosylcytosine 
5-fC 5-formylcytosine 
5-hmC 5-hydroxymethylcytosine 
5-mC 5-methylcytosine 
ADRB2 beta-2 adrenoreceptor 
ALL acute lymphoblastic leukemia 
AML acute myeolid leukemia 
Ann-V Annexin-V 
APOBEC apolipoprotein B mRNA editing enzyme 
ASM allele-specific methylation 
ATM ataxia telangiectasia mutated gene 
ATRX ATP-dependent helicase ATRX 
BAK BCL-2 antagonist / killer 1 
BAX BCL-2 associated X protein 
BC buffy coat 
BCL-2 B-cell lymphoma 2 
BCR B-cell receptor 
BL Burkitt lymphoma 
BMSC bone marrow stroma cells 
CCND1 cyclin D1 
CGI CpG island 
CGU CpG unit 
ChIP chromatin immunoprecipitation 
cHL classical Hodgkin lymphoma 
CIMP CpG island methylator phenotype 
CLL chronic lymphocytic leukemia 
CML chronic myelogenous leukemia 
CMML chronic myelomonocytic leukemia 
DAXX death-associated protein 6 
DLBCL diffuse large B-cell lymphoma 
DMR differentially methylated region 
DMSO dimethyl sulfoxide 
DNMT DNA methyltransferase 
DSB double strand break 
EBF1 early B-cell factor 1 
EMT epithelial-mesenchymal transition 
ER endoplasmatic reticulum 
ER-α estrogen receptor alpha 
ESC embryonic stem cell 
EZH2 enhancer of zeste homolog 2 
FL follicular lymphoma 
GBM glioblastoma multiforme 
GSI y-secretase inhibitor 
H healthy donor 
HNSCC head and neck squamous cell carcinoma 
HRP horse radish peroxidase 
ICGC International cancer genome consortium 
IFN-α interferon alpha 
IGFPB4 insulin-like growth factor-binding protein 4 
IGHV heavy chain variable region 
iNOS nitric oxide synthase 
 X Abbreviations 
iPS induced pluripotent stem cells 
ITAM immunoreceptor tyrosin-based activation motif 
ITGB2 integrin beta 2 
JHDM Jumonji-C domain histone demethylases 
KLF4 Krüppel-like factor 4 
KMT histone lysine methyl transferases 
LEF-1 Lymphoid enhancer-binding factor 1 
LILRA4 leukocyte immunoglobulin-like receptor subfamily A member 4 
LINE-1 long interspersed element 1 
MA MassARRAY amplicon 
MCIp methyl-CpG-immunoprecipitation 
MCL mantel cell lymphoma 
MCL mature B-cell like 
MCL1 myeloid cell leukemia 1 
MDS myelodysplastic syndromes 
miR micro RNA 
MLL mixed lineage leukemia 
MM multiple myeloma 
MPN myeloproliferative neoplasm 
NBC naive B-cell like 
NLC nurse like cell 
NGS next generation sequencing 
NHEJ non-homologous end joining 
NHL non-Hodgkin lymphoma 
NICD NOTCH1 intracellular domain 
NuRD nucleosome remodeling deacetylase 
OS overall survival 
PBMC peripheral blood mononuclear cells 
PBS phosphate-buffered saline 
pDC  plasmacytoid dendritic cell 
pdCR promoter downstream correlating regions 
PFS progression free survival 
PI3K phosphoinositide-3-kinase 
PRC2 polycomb repressive complex 2 
RIPA Radio-Immunoprecipitation Assay buffer 
sAML secondary AML 
Sat-α satellite alpha 
STAT1/6 signal transducers and activators of transcription 1/6 
TAM tumor associated macrophages 
TBE Tris-borate-EDTA 
TBS Tris-buffered saline 
TCGA The Cancer Genome Atlas Research Network 
TERT telomerase reverse trancriptase 
TET ten-eleven translocation 
TF transcription factor 
TFN-α tumor necrosis factor alpha 
TLR7 toll-like receptor 7 
TSS transcription start site 
TP53 tumor protein 53 
UTX ubiquitously transcribed tetratricopeptide repeat, X chromosome 
VHL von Hippel-Lindau 
α-KG alpha-ketoglutarate 
 
 
  
 
XI Abbreviations 
Definitions 
Gene symbols written as capital letters indicate human protein (e.g. KLF4). 
Gene symbols written in italic as capital letters indicate human gene (e.g. KLF4). 
Gene symbols written in lower case starting with a capital letter indicate mouse protein 
(e.g. Klf4). 
Gene symbols written in italic in lower case starting with a capital letter indicate mouse 
gene (e.g. Klf4). 
 
 
  
 XII 
 
  
 
1 Introduction 
I. Understanding the development and progression of cancer 
1. Numbers of cancer incidence reveal the need for new treatment options 
According to Cancer Research UK1 in the year 2012 about 14.1 million new cases of 
cancer occurred worldwide. Among those the four most common entities, which account 
for 42% of all cases, are lung, female breast, bowel and prostate carcinoma (Figure 1).2,3 
In Germany alone, in 2012 about 221,000 deaths were cancer related and in addition, 
about 0.5 million new cases registered.4,5 This number was shown to increase over the 
last decade, which is partly caused by the demographic change as the cancer incidence 
for over 80-year old is about 200 to 300 fold higher than for kids with age under 15 years.6 
Although, since the 1970s, the overall survival rate of all cancers has increased from 
about 25% to 50% due to faster diagnosis and advanced treatment options, it is estimated 
that about four in ten cases of cancer could still be prevented. Environmental factors and 
lifestyle including smoking, alcohol, UV light and certain infections, have a profound 
influence on cancer development. For example, tobacco smoking is currently responsible 
for more than one in five cancer cases among men and nearly one in twelve among 
women in Germany.7 Furthermore, primary prevention measures for early cancer 
diagnosis like screenings of skin, breast and prostate, could further reduce cancer 
mortality. This is shown by an increased incidence of skin cancer in 2008 after the 
introduction of preventive screening in Germany.8 
 
      
Figure 1. Cancer statistics in the year 2012 worldwide. (A) Incidence and mortality of cancer worldwide in 
the year 2012. (B) The 10 most commonly diagnosed cancer 2012 estimates. Total number and percentage of 
new cases diagnosed per year, worldwide. Modified from www.cancerresearchuk.orgI 
But still, some types of cancer like lung and pancreas cancer show very little improvement 
and low survival rates causing about 90% of patients to die within 10 years after 
diagnosis. This led to about 8.2 million cancer related deaths in the year 2012 worldwide 
(Figure 1). In addition to the prevention of cancer, there is still a strong need for new and 
improved diagnostic tools and treatment options which could avert cancer related deaths 
via early onset and more efficient disease management. To gather these tools it is 
                                            
I Statistics are from the International Agency for Research on Cancer GLOBOCAN database and also the World Health 
Organization Global Health Observatory and the United Nations World Population Prospects report. 
 2 Introduction 
necessary to further expand our understanding of the molecular characteristics underlying 
the development and progression of cancer. 
2. Defining the molecular characteristics of cancer 
On cellular level, cancer is a disease of the body’s own cells. Triggered by some 
environmental, microenvironmental or intrinsic stimuli, cells of various types can start 
growing and cause previous healthy tissue to develop tumors. This oncogenesis is a 
multistep process which can be seen as a sequence of clonal expansions. These are 
believed to be based on genomic instability and the inflammatory state of the cells and 
their surrounding tissue as well as their microenvironment. In line with this process, the 
neoplastic cells need to acquire functional skills which allow them to survive, proliferate 
and disseminate.  
 
 
Figure 2. The 8+2 hallmarks of cancer. Interplay of all hallmarks represents the molecular basis for cancer 
development and progression. Modified from Hanahan & Weinberg et al.9 
In the year 2000 Hanahan and Weinberg first defined such capabilities which they called 
the 6 hallmarks of cancer. They later amended these hallmarks, resulting in 8 biological 
aptitudes cells acquire during their multistep development of human tumors. These 
include (1) sustaining proliferative signaling, (2) evading growth suppressors, (3) resisting 
cell death, (4) enabling replicative immortality, (5) inducing angiogenesis, (6) activating 
invasion and metastasis, (7) reprogramming energy metabolism and finally (8) evading 
immune destruction (Figure 2). Further, the two “enabling characteristics”, genomic 
instability and inflammation, were defined which seem to act as the basis for cancer 
development.9,10 However, most hallmarks are tightly connected and moreover influenced 
by the tumor microenvironment and epigenetic changes within the cancer cells.  
  
 
3 Introduction 
2.1. Disruption of genomic stability is supposed to trigger tumor 
development 
In cancer, the integrity of the genomic stability can be disturbed by mutations, which can 
affect the activity or expression of oncogenes as well as tumor suppressor genes. In 
addition, chromosomal rearrangements can lead to the formation of fusion genes. Due to 
the high impact of these genetic aberrations on the development of cancer, networks like 
the ICGC Cancer Genome Project (www.ICGC.org) and The Cancer Genome Atlas 
Research Network (TCGA; www.cancergenome.nih.gov) are using large scale next 
generation sequencing (NGS) to obtain a comprehensive description of genomic, 
transcriptomic and epigenomic changes in different tumor types.11,12 Hence, new recurrent 
mutations have been identified in close to all cancer entities, as well as new chromosomal 
rearrangements.  
One of the most prominent fusion genes that was already discovered in 1960 is the BCR-
ABL fusion gene which results from a translocation between chromosomes 9 and 22 
giving rise to the so called Philadelphia chromosome.13 It is associated with chronic 
myelogenous leukemia (CML) with 95% incidence in these patients and also to a lesser 
extend (25-30%) with acute lymphoblastic leukemia (ALL) and other leukemias.14 The 
protein ABL is a tyrosine kinase which in its BCR-ABL fusion form is constitutively active 
and influences transformation of the cells by activating downstream signaling like the 
NFκB and PI3K/AKT pathways.15–17 In addition, BCR-ABL was recently shown to cause 
increased acetylation of p53 which protects the cells from mitochondria-dependent 
apoptosis in response to DNA damage.18  
TP53 (tumor protein 53) which was also referred to as the “guardian of the genome” is 
one of the most recurrently mutated and deregulated tumor suppressors in the course of 
cancer. The gene gives rise to the protein p53, which can act as tetrameric transcription 
factor that functions to induce cell cycle arrest or apoptosis after the detection of 
chromosomal and cell cycle abnormalities as well as hypoxia. Further, it can directly 
interact with members of the BCL-2 family of apoptotic and anti-apoptotic proteins like 
PUMA and NOXA and translocate to the mitochondria to induce cell death.19,20 Loss of 
p53 function is a strong inducer of cancer and as mentioned before, it was shown to be 
mutated in various types including mammary carcinoma, medulloblastoma and chronic 
lymphocytic leukemia (CLL).21–23 The effect of the mutations is diverse, resulting in most 
cases in a loss of the wild type function of the protein and in some cases a gain-of-
function that helps to contribute to malignant progression and earlier cancer onset.24–28  
Interestingly, in medulloblastoma and other tumors, TP53 mutations were recently linked 
to another phenomenon observed in cancer cells, the shattering of whole chromosomes 
resulting in catastrophic genome rearrangements.29 This event, called chromothripsisII, 
provokes a high number of gene fusions, disruption of tumor suppressors and 
amplification of oncogenes.30 Originally, it was first detected in a case of CLL but since 
then it has been associated with many other cancer entities and shows an incidence of 
about 2-3% depending on the type of cancer. It was associated with poor outcome of the 
patients in multiple myeloma (MM), AML and melanoma.29,31,32 The mechanisms 
underlying this catastrophic event are still unclear, but two possible scenarios were 
suggested: (I) DNA damage caused by ionizing radiation and (II) critical telomere 
                                            
II Chromothripsis composed from the Greek words chromos which represents chromosomes and thripsis which means 
“shattering into pieces” 
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shortening.30 In the first case, radiation induced double strand breaks (DSBs) are repaired 
by low-fidelity and error prone repair mechanisms like non-homologous end joining 
(NHEJ) which could explain the massive rearrangements. Of note, NHEJ was shown to 
play a greater role in the repair of DSBs when p53 activity is reduced.33 Another 
hypothesis is that chromothripsis is the result of critical telomere shortening followed by 
chromosome end-to-end fusion and subsequent breakage.34 This is further supported by a 
higher incidence of chromothripsis in AML patients with advanced age at diagnosis.29 
Unprotected telomeres in p53-deficient cells were found to be shorter than average and 
prone to form end-to-end fusions which could again point towards a possible connection 
between chromothripsis and p53 activity. However, so far it is still unclear whether TP53 
mutations predispose cells for chromothripsis or rather enable the cells to survive after the 
catastrophic chromosome shattering. It also remains to be elucidated if cases of 
chromothripsis, which are not connected to precedent TP53 mutations, show other 
deregulation of the p53 pathway. 
Another striking phenomenon which was discovered in recent years is the so-called 
kaetegisIII. This term describes areas of localized hypermutations, which were first found 
in breast cancer cells. Often these mutation clusters co-localize with clusters of genomic 
rearrangements and in addition, the same type of mutations occur over several 
megabases.35,36 By now the APOBEC-family (apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like) of cytosine deaminases are thought to be associated with 
kaetegis. They are a known source of DNA damage, and APOBEC binding motifs seem to 
be enriched in the affected areas.37 
The exact mechanisms underlying the events of chromothripsis and kaetegis remain to be 
clarified, but confirm the assumption that genomic instability is one of the key factors 
determining the development of cancer and giving rise to the hallmarks. 
2.2. Activating the proliferative capacity of cancer cells 
The sustainment of (1) proliferative signaling and (2) evading growth suppressors are two 
hallmarks which directly interact. In contrast to normal cells, cancer cells acquire the 
ability of chronic proliferation by deregulating growth factor mediated, kinase-dependent 
and -independent intracellular signaling cascades. These signaling pathways, which 
normally serve to maintain normal tissue architecture and function, are manipulated by the 
cancer cells. For this purpose the cells can either enhance autocrine proliferative 
stimulation or trigger other cells to provide the necessary stimuli. This was shown for 
fibroblasts in mammary carcinoma and tumor associated macrophages (TAMs) in several 
types of tumors.38–40 In other cases, the amount of receptors on the cell surface can be 
increased or constitutive activation of signaling pathways can circumvent the necessity of 
external stimulation of the cells altogether.41 One striking example for this is the PI3K/AKT 
pathway which is hyperactivated in about 30% of invasive breast cancer. Causative for 
this activation are gain-of-function mutations in members of this pathway including 
mutations in the catalytic subunit of PI3KCA, AKT1 and amplification of AKT2. This is 
accompanied by a disruption of a negative feedback loop through loss-of-function 
mutations of the PTEN phosphatase, which otherwise counteracts PI3K activity.42–45  
In addition to increased proliferation, the cancer cells are able to evade growth 
suppressors amongst other effects by avoiding contact inhibition. For example, the tumor 
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5 Introduction 
suppressor MERLIN, which is encoded by the gene NF2 (neurofibromatosis factor 2), 
mediates contact-dependent inhibition of proliferation by stabilizing adherent junctions and 
negative regulation of epidermal growth factor receptor (EGFR). Loss or mutations of NF2 
was shown to result in cell proliferation and tumorigenesis.46–48  
2.3. Replicative immortality enables nonfinite tumor growth 
Normal cells go through a limited number of successive cell cycles before they either 
reach a viable but non-proliferative state, cell senescence or go into cell death. However, 
in cancer some cells escape the underlying mechanism which enables them to reach 
(4) replicative immortality. It is believed that telomeres which protect the ends of 
chromosomes sustain the capability of cells for unlimited proliferation. In fact, the enzyme 
telomerase which is necessary for maintaining functional telomeres, is almost absent in 
most non-immortalized cells whereas expressed in most immortalized cells. This would 
suggest that in cancer cells, either the up-regulation of telomerase or recombination 
based telomere maintenance would be able to preserve the cells in a persistent replicative 
state.49–51 However, as mentioned before it was shown that shortened telomere length 
increases the risk to develop cancer, probably due to decreased chromosome integrity 
and stability. It even seems that transient telomere deficiency during the early stages of 
cancer development facilitates malignant progression.52–55 It is known that telomerase, 
especially its subunit TERT (telomerase reverse transcriptase), has additional functions 
which include the interaction with the NFκB pathway, amplifying WNT signaling, RNA 
polymerase function, impact on DNA damage repair and cell proliferation as well as 
mediating resistance to apoptosis.56–61 
2.4. Evading cell death and senescence 
Another requirement for tumor formation is for the cells to circumvent the machineries 
triggering apoptosis, autophagy and necrosis and hence (3) to resist cell death. In the 
case of apoptosis upstream and downstream effector components are necessary which 
can prompt an extrinsic and intrinsic apoptotic program. By now it is known that the 
apoptotic state of a cell is in part determined by a balance of members of the B-cell 
lymphoma 2 (BCL-2) protein family, which are in a tight interplay with other proteins like 
p53, as mentioned before. One or more BCL-2 homology domains (BH) that regulate 
interactions among the family members characterize these proteins. The anti-apoptotic 
family members (e.g. BCL-2, BCL-XL, MCL-1) and pro-apoptotic proteins (e.g. BIM, BID, 
NOXA and PUMA) can directly interact and hence sequester or inhibit each other’s 
effects.62,63 BCL-2 itself for example, acts via binding the BH3-only proteins BAX and BAK 
and thus prevents the formation of a homodimeric complex in the mitochondria 
membrane.64 This complex otherwise destroys the integrity of the mitochondria and 
consequently results in the release of Cytochrome c which again activates caspases with 
proteolytic activity causing the cells to go into apoptosis.65 Some of the anti-apoptotic 
proteins like BIM antagonize this mechanism by binding to BAX/BAK, blocking its 
interaction with BCL-2 and directly activating the pro-apoptotic complex.66 Another 
member, Beclin-1, was shown to trigger autophagy as long as it is not bound by BCL-2 or 
BCL-XL which again can be inhibited by the influence of the other anti-apoptotic family 
members. In fact, some cancers like T-ALL are dependent on anti-apoptotic proteins like 
BCL-2 and show a down-regulation of others like Beclin-1.67–71 While apoptosis and 
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autophagy are counteracted and circumvented by cancer cells, necrotic cells can recruit 
inflammatory cells which display tumor promoting effects.72,73 
2.5. Tumor-associated neovasculature ensures tumor maintenance  
As any other type of tissue, tumors are dependent on tumor-associated neovasculature 
which facilitates the delivery of necessary nutrients and oxygen as well as the disposal of 
metabolic waste. In general, stimulatory and inhibitory cell-surface receptors on vascular 
endothelial cells like VEGF-A can trigger ligand induced vessel growth and were shown to 
be up-regulated under hypoxic conditions and through oncogene signaling.74,75 On the 
other side, endogenous angiogenesis inhibitors like TSP-1, Angiostatin, Endostatin and 
various interleukins counteract this mechanism and their increase was shown to impair 
tumor growth in different in vitro and in vivo models.76–80 Anyway, most important for the 
process of tumor angiogenesis induction, the angiogenic switch, is the tumor 
microenvironment with pericytes, the extracellular matrix, endothelial precursor cells and 
cells which are recruited via inflammatory processes.81 The latter include different types of 
bone marrow derived cells being part of the inert immune system like macrophages and 
neutrophils which can promote angiogenesis in vivo and stimulate tumor growth.82–84 
Pericytes act as bystander cells for endothelial cells, attached to the outer surface of 
normal tissue vasculature and were shown just to be as important for tumor-associated 
neovasculature.85 In addition, to inflammatory processes, hypoxic conditions in the tumor 
cells and its environment can induce factors like HIF1-α which in turn drives the release of 
pro-angiogenic factors like VEGF further supporting the angiogenic switch.75,81,86 Due to its 
high importance for maintaining a functional tumor structure, tumor vasculature is a 
promising target in cancer therapy and in line with this a number of inhibitors like 
Sorafenib and Sunitinib acting on angiogenic stimulators like VEGF are currently under 
investigation as cancer therapeutics.87,88 
2.6. Targeting and preventing tumor metastasis is necessary to fight cancer 
One big challenge in the treatment of many types of cancer is not only to kill the tumor 
itself but also to prevent its progression into other organs and tissues where it can build 
metastasis. The formation of these secondary metastatic tumors happens in a multistep 
process, the invasion-metastasis cascade, which is similar to the so called epithelial-
mesenchymal transition (EMT). In healthy organisms, EMT is necessary for wound 
healing and developmental processes in adults and during embryogenesis.89,90 However, 
in the case of cancer, tumor cells migrate into the stroma of the tumor surrounding tissue 
and intravasate into the vascular system in which they circulate to new sites of the body. 
Upon extravasation, the cancer cells form micrometastatic lesions which adapt to the new 
microenvironment and evolve into metastatic tumors. It is assumed, that throughout the 
initial stage of EMT in healthy tissues as well as tumors, the cells are to some degree 
pushed towards a stem cell-like state. This process is regulated by a tight network of 
epigenetic modifications, differential splicing, small non-coding RNAs and over all on the 
level of transcription.91–93  
Three families of EMT-transcription factors (EMT-TFs), namely SNAIL, ZEB and TWIST, 
play a central role in this network. One of their main functions is the repression of CDH1 
which codes for the protein E-cadherin which again is essential for EMT progression as it 
helps to maintain epithelial cell sheets. In line with that, EMT-TFs were shown to interact 
with epigenetic modifiers and are involved in a genome-wide epigenetic reprogramming 
  
 
7 Introduction 
taking place during the initial stage of EMT.94–97 TWIST for example can interact with the 
NuRD (nucleosome remodeling deacetylase) chromatin remodeling complex and 
polycomb proteins, hence recruiting them to the promoter of CDH1 to induce its 
transcriptional repression.98,99 SNAI1, a member of the SNAIL family, can in addition 
recruit HDAC1 and -2 for the same purpose and moreover the expression of CDH1 is also 
regulated via DNA methylation in cancer.100,101 It is also known that EMT-TFs interact with 
two families of tumor suppressor micro RNAs (miR), the miR-200 and the miR-34 
family.102–105 Members of both classes of miRs can be down-regulated, amongst other 
aspects by promoter hypermethylation, in cancer and are directly interacting with the 
EMT-TFs.92,93,106 For example, SNAI1-dependent EMT is activated in colon, breast and 
lung carcinoma cells but can be blocked by miR-34 which binds to the 3’UTR of SNAI1 
itself as well as key SNAI1 regulatory molecules including ß-catenin. The miR-200 family 
is a marker for high expression of CDH1 in cancer cells and was further proven to regulate 
the E-cadherin repressors ZEB1 and ZEB2. In addition, up-regulation of miR-200 
members is sufficient to prevent TGF-ß induced EMT, underlining its strong involvement 
in the course of this process.102,103 
Of great interest is also the role of alternative splicing during the transmission of the 
cancer cells. The epithelial splicing regulator genes ESRP1 and ESRP2, which can be 
regulated by EMT-TFs, are able to induce ESRP-enhanced or -silenced exon splicing 
changes of over 200 genes.107 FGFR2, RON and CTNND1 (p120 catenin) are among the 
most prominent examples.108,109 CTNND1 has a short epithelium-specific isoform which 
promotes cell-cell adhesion by stabilizing E-cadherin at the plasma membrane. Its long 
isoform is expressed during EMT and supports invasiveness of the cells.110  
Besides these intracellular mechanisms, necessary for the metastatic capacity of the 
cancer cells, migration and invasion are also dependent on the support of the tumor 
microenvironment that has to be permissive and also supports the tumor in other aspects 
as mentioned before. 
2.7. Tumor promoting inflammatory processes and the tumor 
microenvironment 
Tumors are infiltrated by cells of the immune system and it was thought for a long time 
that the immune system tries to eradicate the tumor cells. Although this might be true to 
some degree, it is now assumed that the tumor-associated inflammatory processes rather 
enhance tumorigenesis and progression.111 Growth factors and survival stimuli secreted 
by cells of the immune system can stimulate proliferation of cancer cells and support 
invasion and angiogenesis as already mentioned above. Many of the major inflammatory 
pathways in cancer converge at level of transcription factors like STAT3 and NFκB. 
Proliferative and survival stimuli activate growth factor receptor tyrosine kinases on the 
surface of the cancer cells. A few major downstream cascades including the STAT3 
pathway and other members of the STAT family are activated and could be linked to 
inflammatory processes in cancer.112 STAT3 for example was shown to be activated by 
IL-6 which can be secreted by myeloid cells and leads to an up-regulation of cell cycle 
regulators, the oncogene MYC and anti-apoptotic genes of the BCL-2-family.113 In 
addition, NFκB signaling functions as tumor promoter in inflammation associated cancer 
for example by enhancing WNT-ß-catenin signaling which was shown to induce 
dedifferentiation of intestinal non-stem cells that acquired tumor-initiating capacity.114 
NFκB-dependent inflammatory response on the other hand can mediate increased IL-6 
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expression which leads to the amplification of the NFκB-IL6-STAT3 cascade in cancer 
cells. However, this is just one example for the complex mechanisms which include 
inflammatory processes and the cells of the immune system in the promotion of tumor 
development.  
Not only inflammatory processes but also other aspects and cells of the tumor 
microenvironment are currently under close investigation as they seem to be important not 
only for tumor development but also for disease maintenance. This will be discussed in 
greater detail, using the example of CLL, below. 
3. Cancer epigenetics 
One further characteristic of tumor cells which could be included in the hallmarks of 
cancer are changes in the cancer epigenome. We know now that not only mutations and 
chromosomal aberrations but also changes in DNA methylation, histone modifications and 
the chromatin structure can result in the deregulation of oncogenes, tumor suppressor 
genes as well as non-coding RNAs. Some examples were already mentioned before but 
as the epigenome, especially DNA methylation in cancer, is central for the project 
described here, it will be discussed in greater detail. 
3.1. Cancer is characterized by global hypomethylation, DMRs and CIMPs 
In the last two decades, the establishment of high-throughput techniques for the genome 
wide analysis of DNA methylation has led to a greater understanding of the distribution of 
this DNA modification and its role in the regulation of gene expression. Until recently, DNA 
methylation was mainly thought to impact on gene expression when present in the 
promoter regions, where high methylation is associated with repression of the associated 
genes.115 A striking example is the silencing of the inactive X chromosome in women 
which is maintained by highly abundant DNA methylation in the promoter regions of 
almost all genes localized on this chromosome.116 However, not only methylation in 
promoters but also in gene bodies impacts on transcriptional activity, however displaying 
positive correlation with gene expression and marking enhancer regions.117 Besides its 
role in controlling gene expression, tissue specific intragenic DNA methylation was shown 
to result in alternative splicing. Moreover, a genome wide methylation study in prostate 
cancer indicates that differential methylation could define alternative transcription start 
sites (TSS) as well.118,119 Furthermore, DNA methylation was shown to be important for 
centromere integrity and telomere length. Changes in the DNA modification on repetitive 
elements are associated with differentiation and embryonic development.120–122 
Nevertheless, one has to keep in mind that DNA methylation is dynamic and varies 
between different types of tissues and differentiation stages. Considering its important role 
in developmental and cell maintaining processes, it is not surprising that changes in DNA 
methylation patterns were by now associated with many types of diseases including 
cancer. 
For the first time, in 1983 Andrew Feinberg and his group showed a pattern of global 
hypomethylation in small cell lung cancer and colon adenocarcinoma in comparison to 
healthy tissue counterpart.123 Today we know, that global DNA hypomethylation occurs in 
most types of cancer including hematological disorders like CLL, breast and colorectal 
cancer but also that most cancers show a divergent epigenetic landscape. The latter is 
defined by cancer specific differentially methylated regions (DMRs) which especially also 
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include CpG islands (CGIs).124–128 About 29,000 of these regions with high CG content 
(>50%) were found in the human genome and are known to be usually unmethylated 
throughout all stages of development and in all types of tissue.129,130 In cancer however, 
about 5% to 10% of CGIs show strong methylation resulting in a so called CGI methylator 
phenotype (CIMP). CIMPs, amongst others, were identified in colorectal cancer and 
glioma where the high frequency of hypermethylation supports the idea of a coordinated 
event rather than a stochastic phenomenon.131,132 In line with that, the CIMP of glioma is 
associated with IDH1 mutations, which are known to impact on DNA methylation.133 
Besides changes in direct CGI methylation, regions adjacent to CGIs, so called CGI 
shores and shelves are currently under investigation as they show tissue specific DNA 
methylation and were found to be hyper- and hypomethylated in cancer.134,135 CGI shores 
and shelves are also part of recently discovered promoter downstream correlating regions 
(pdCRs). They often extend tens of kilobases or more from TSS and were found in about 
8% of expressed genes in medulloblastoma. Interestingly, methylation and expression 
levels of genes harboring a pdCR could distinguish between the WNT, SHH, group3 and 
group4 subgroups of medulloblastoma. Besides that, these huge DMRs revealed to be a 
universal feature present in various types of tissue.136  
Whether the high degree of aberrant DNA methylation is cause or consequence of cancer 
development remains to be elucidated, but it is clear by now that the effects are 
tremendous. On the one hand, hypomethylation was shown to strongly correlate with 
genomic instability. On the other hand, hypermethylation permits or prevents the binding 
of transcription factors and methyl binding proteins like MBD1, 2 and 3 as well as MeCP2, 
which can recruit histone modifiers and other chromatin remodelers resulting in the down-
regulation of tumor suppressor genes and miRNAs. Some examples are TP53 in ALL, 
BRCA1 in breast cancer and the DNA repair enzyme MGMT in glioma as well as the 
miR-200 and miR-34 families which were already described above as interaction partners 
and regulators of EMT-TFs and which are hypermethylated in breast and prostate cancer, 
respectively.92,93,106,137–141 
3.2. New emerging DNA modifications in mammals: 5-hmC, 5-fC and 5-CaC 
For a long time 5-methylcytosine (5-mC) was supposed to be the only DNA modification in 
mammals. Recently, 5-hydroxymethylcytosine (5-hmC) was discovered as a so called 6th 
base in mouse embryonic stem cells (ESC) and Purkinje Neurons. By now it is known that 
5-hmC is generated through oxidation of 5-mC by the ten-eleven translocation protein 
family (TET) members TET1 to 3.142–144 Furthermore, these enzymes catalyze the 
conversion of 5-hmC to 5-formylcytosine (5-fC) and subsequently to 5-carboxylcytosine 
(5-CaC) which can then be excised from the DNA by thymine DNA glycosylase in the 
process of linked deamination base excision repair (Figure 3).145 Hence, these three DNA 
modifications were identified as intermediates in an active demethylation pathway.  
However, recently several groups investigated the genome wide distribution of 5-hmC 
using either high throughput sequencing of 5-hmC containing DNA or analysis of the latter 
on micro arrays.147–150 These groups all found a similar pattern of 5-hmC distribution in 
mouse ESCs, ES cell lines, mouse cerebellum and human brain frontal lobe tissue. Most 
of the 5-hmC enriched regions were within gene bodies, CGIs and gene promoters while 
the modification was depleted in repetitive and intergenic regions. Moreover, 5-hmC was 
present in CTCF and pluripotency transcription factor binding sites.147,149 The majority of 
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the 5-hmC enriched regions were associated with moderate CpG density. It was also 
observed that intragenic and proximal enrichment of 5-hmC is associated with more highly 
expressed genes.147,148,150 In line with this observation, initial evidence was provided that 
5-hmC contributes to both transcriptional activation and repression in a context-dependent 
manner.148 These findings indicate that at least 5-hmC and potentially also 5-fC and 5-
CaC have specific functions and are not just demethylation intermediates. First screens 
have identified a number of proteins potentially binding to all three modifications, but this 
has to be evaluated in detail and the functional role of such interactions are still to be 
determined.151–153 
 
Figure 3. The conversion pathway of emerging DNA modifications. TET proteins can convert 5-mC to 5-
hmC, 5-fC and 5-CaC. Passive demethylation via replication of active demethylation via base excision repair 
is possible. TET proteins are dependent on α-KG for enzyme activity which is provided by IDH1 and 2. 
Modified from Mariani et al.146 
Besides its specific genome wide distribution, the level of 5-hmC in healthy tissue seems 
to be an indication for the differentiation state of the cells, with higher 5-hmC levels 
correlating with differentiation.154 In cancer cells, the overall levels of 5-hmC are reduced, 
similar to the global hypomethylation seen for DNA methylation. For example, melanoma 
cells show significantly low levels of hydroxymethylation genome wide, while increased 
levels of DNA methylation could be detected in gene bodies and promoter regions, 
presumably due to lack of oxidation.155 A similar loss of global 5-hmC could be detected in 
pancreatic cancer, accompanied by enrichment of this modification in exons and 
transcription factor binding sites.156 It is known that loss of DNA methylation can be either 
result of active demethylation via 5-hmC, deamination or passive loss of methylation 
during replication. For loss of 5-hmC in cancer cells two reasons are currently under 
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investigation: inhibition of the TET proteins via IDH1/2 mutations or inactivating mutations 
of the TET members themselves. 
Especially in hematological diseases mutations of TET1 and 2 as well as IDH1 where 
shown to play an important role. In AML, MPN, sAML after MPN, MDS, systematic 
mastocytosis and CMMLIV TET2 shows an overall mutation rate of 19.5% which indicates 
a biological relevance and a potential impact on the course of these myeloid diseases. A 
wide range of 237 different somatic mutations were detected for TET2 ranging from 
missense over nonsense mutations to frameshifts.157–166 Although, it was possible to trace 
TET2 mutations back to CD34+ progenitor cells and T-cells in some cases, the question if 
the mutations are in general an early event in cancer development is still open.167,168 This 
assumption is however supported by the finding that Tet2-deficient mice develop 
hematopoietic malignancies similar to CMML. Thus it appears that even the lineage 
determination in the hematopoietic system is controlled in part by deposition of 5-mC and 
5-hmC which controls lineage specific gene silencing.169,170 TET1 was found to be a fusion 
partner of the MLL (mixed lineage leukemia) protein in cases of acute lymphoblastic 
leukemia. Translocations, which create fusion genes with MLL, are associated with 
truncation of the protein and often predict a poor prognosis in ALL. However, no somatic 
mutations of TET1 have been found in MPN, chronic myelomonocytic leukemia or AML so 
far.157 
Remarkably, mutations of IDH1 and 2, which were found in several types of cancer, result 
in a change of the catalytic activity of the enzymes and henceforth, the production of 2-
hydroxyglutarate (2-HG) from isocitrate instead of α-ketoglutarate (α-KG) (Figure 3). The 
TET proteins which normally need α-KG to catalyze the oxidation of 5-mC to 5-hmC and 
its other derivatives are inhibited by 2-HG, which hence results in a hypo-
hydroxymethylation phenotype.171–175  
3.3. Altered chromatin structure is associated with DNA methylation and 
genomic mutations in cancer 
Besides the effect of DNA modifications, chromatin conformation and activity are 
influenced by the position and composition of nucleosomes. So-called chromatin 
remodelers are responsible for altering nucleosome structures by the introduction of 
histone modifications and variants. These remodelers therewith guide the accessibility of 
promoter regions, enhancers and other regulatory domains and mediate the binding of 
transcriptional regulators. More and more evidence suggest that genomic mutations of 
involved proteins as well as fluctuations in their activity effect changes in chromatin 
composition and hence, activity in various types of cancer. 
The most abundant nucleosomes are composed of an octamer of histones containing two 
of each histone H2A, H2B, H3 and H4 which are wrapped by about 146 bp of DNA. 
However, in order to change nucleosome compositions chaperons like e.g. CHZ1, FACT 
and ASF1, can bind to the nucleosomes and replace the classical canonical histones by 
variants.176–178 By now, whole families of histone variants could be identified including the 
H2A family which includes the classical H2A, but also other members like H2A.X, H2A.Z, 
macroH2A and H2A.B as well as isoforms and splice variants thereof. Of this family the 
most prominent member, besides H2A itself, is H2A.Z of which the incorporation is 
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replication independent and which can have pleiotropic effects on genome stability, 
transcriptional regulation, epigenetic memory and heterochromatin boundaries.179–182 In 
cancer, high H2AFZ expression, the gene coding for H2A.Z, was found to be associated 
with lymph node metastasis and decreased survival in breast cancer. Apparently, H2AFZ 
overexpression promotes proliferation of breast cancer cells by integrating of the protein 
into promoter regions of estrogen receptor alpha (ERα) target genes and hence regulation 
of estrogen-mediated signaling.183,184 
Another example is H3.3 which is a variant of H3 and one of the best characterized 
histone variants. H3.3 containing nucleosomes are less stable and are associated with 
telomeres, pericentric regions and active gene promoters. Furthermore, they are 
incorporated in upstream regulatory regions upon induction of transcription, thus 
promoting transcriptional elongation. Like for H2AZ, integration of H3.3 is replication 
independent and depends on chaperones like ATRX and DAXX.185–188 Both genes were 
found to be mutated in several GBMs (glioblastoma multiforme) resulting in increased 
alternative lengthening of telomeres and genomic instability. In addition, mutations of 
H3F3A, one of two genes coding for H3.3, found in high grade gliomas correlate with 
global reduction of H3K27me3 and aberrant recruitment of the polycomb repressive 
complex PRC2 as well as inhibition of the histone methyltransferase EZH2 (enhancer of 
zeste homolog 2).189–191 
Most chromatin remodelers are recruited by histone modifications, some of which are 
methylation, acetylation, phosphorylation and ubiquitinylation. Depending on the histone 
type and the affected amino acid residues, the modifications can have activating, 
repressing or bivalent effects on gene expression and regulatory elements. They are 
initiated by so-called “chromatin writers” like acetyl- and methyltransferases and 
recognized by “readers” which often contain bromodomains or PhD fingers. These 
domains enable them to recognize and bind histone modifications and subsequently 
recruit further transcriptional repressors or activators.192 
Many of these genes were by now shown to be mutated or aberrantly expressed in 
cancer, resulting in or caused by cancer specific patterns of histone modifications. For 
example, histone lysine methyl transferases (KMTs) like EZH2 and MLL2 mediate the 
mono-, di- and tri-methylation of histones. MLL2 is mutated in 90% of follicular lymphoma 
(FL) and in some cases of medulloblastoma where it is suspected to be involved in the 
generation of subtype-specific aberrant patterns of H3K4 and H3K27 methylation.193–195 
Overexpression of EZH2 is associated with poor prognosis in prostate and breast 
cancer.196,197 Moreover, EZH2 was also found to be mutated in diffuse large B-cell 
lymphoma (DLBCL) and FL which results in increased levels of the repressive histone 
mark H3K27 tri-methylation (H3K27me3) in these tumors. Besides its histone 
methyltransferase activity EZH2 is a polycomb group protein and acts as part of the PRC2 
complex. Interestingly, PRC2 is mainly recruited and active at bivalent promoters 
harboring the repressive mark H3K27me3 and the active mark H3K9me3. In cancer, an 
association between DNA hypermethylation and genes with bivalent histone modification 
was found. These genes have a low poised transcriptional state and in ESCs they were 
shown to maintain stemness and self-renewal. In colon and breast cancer the methylation 
state of these genes can be used to classify and cluster subgroups which points toward 
controlled mechanisms connecting DNA methylation, bivalent histone marks and gene 
expression.198–201 
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Another prominent histone modifier is UTX, a histone H3 lysine demethylase which was 
found to be mutated in about 12 different types of cancer including ALL, CML, and 
glioblastoma. Van Haaften and colleagues could show that upon reintroduction of 
functional UTX in mutated cells, proliferation was slowed down and transcriptional 
changes could be detected, pointing on the functional impact of de-functional histone 
modifiers.202–204  
As mentioned before, it was shown that IDH1 mutants found in myeloid malignancies and 
glioblastoma are able to produce 2-HG from α-KG and that these mutations could be 
associated with a hypermethylation phenotype. Interestingly, some demethylases like for 
example the Jumonji-C domain histone demethylases (JHDMs) use α-KG as substrate 
and their activity can, like TET protein activity, be inhibited by 2-HG. In fact, gliomas with 
IDH mutations compared to tumors with wild-type IDH show dysregulation of global 
histone methylation, an effect which could also be confirmed in vitro. 171,173,189,205 
Histone acetylation marks open and active chromatin and is mediated by histone lysine 
acetyltransferase like the p300-CBP coactivator family. CBP as well as p300 are known 
as transcriptional activators not only because of their acetyltransferase activity but also 
because of interactions with transcription factors like p53 and cMYB. p300 and CBP were 
shown to be mutated in cancer, effected by chromosomal translocations for example in 
therapy related myeloproliferative disease, and their expression is associated with poor 
prognosis in small cell lung cancer. 175,206–208 
The fact that DNA methylation, histone modifications as well as mutations and expression 
changes in chromatin remodelers could be detected in cancer and associated with 
disease state, development as well as prognosis, highlights these factors as potential 
targets in the treatment of cancer. A whole panel of epigenetic treatment options are 
currently under investigation and also already used in the clinics including HDAC inhibitors 
like Vorinostat or Romidepsin, BRD inhibitors like JQ1 and demethylating agents like 
Decitabine and an inhibitor of mutated IDH1 AG-120. 
5-aza-2’-deoxycitidine, commercially available under the name Decitabine (Dacogen), is a 
cytidine analog which, after incorporation into DNA during replication, inhibits the activity 
of DNA methyltransferases (DNMT). These proteins maintain DNA methylation during 
replication (DNMT1) and introduce de novo DNA methylation for example during 
embryogenesis (DNMT3A and B). As described above, DNA methylation in cancer is 
disrupted on several levels resulting in the deregulation of tumor suppressor genes and 
regulatory elements and impact on genomic instability. The use of Decitabine was initially 
indicated for the treatment of myelodysplastic syndrome but until now it is also used in 
current treatment trials against AML, CML and ALL where a positive response could be 
observed.209 The exact mode of action in the cells however in some cases remains 
unclear. While in fact, global hypomethylation was observed in ALL patients in a combined 
trial of Decitabine and Vorinostat in combination with chemotherapy, no changes in DNA 
methylation and target gene expression could be seen in CLL and non-Hodgkin 
lymphoma (NHL) upon Decitabine treatment.210–212 Although Decitabine was only 
approved for hematological malignancies for quite some time, it is currently also under 
investigation as treatment option in solid tumors like ovarian and colorectal cancer.213,214 
Another line of epigenetic treatment are BET family inhibitors. BET family members like 
BRD4 are chromatin remodelers which have bromodomains that recognize mono-
acetylated lysine residues on N-terminal histone tails. Together with the associated co-
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activator Mediator, BRD4 builds a complex that is involved in the control of transcriptional 
elongation by RNA Polymerase II. In multiple myeloma the BRD4-Mediator complex was 
found to co-occupy thousands of enhancers including a small set of exceptionally large 
super-enhancers which are associated with feature oncogenes of MM including MYC.215 
BRD4 inhibitors lead to the depletion of BRD4 at the MYC enhancer and to the down-
regulation of MYC as well as cMYC target genes resulting in anti-proliferative effects, 
associated with cell cycle arrest and senescence not only in MM but also in AML and 
Burkitt lymphoma (BL).216–218 So far no BET inhibitors are used in the clinic but several are 
under investigation and being optimized for use in clinical trials.219 
4. Chronic lymphocytic leukemia 
Chronic lymphocytic leukemia (CLL) is diagnosed in patients which show accumulation of 
small, mature-appearing B-cells in the bone marrow, lymphoid tissues and peripheral 
blood with at least 5x109 B-cells/l.220 CLL cells are arrested in early G0 late G1 phase of 
the cell cycle and in addition show an apoptotic defect which leads to enrichment of the 
malignant cells in the patient. The cells display a specific immunological profile with weak 
levels of IgM and / or IgD as well as expression of CD23, CD19, CD20 and CD5.221 
Amongst other aspects, CLL is a disease of the genome and the epigenome 
characterized by genetic aberrations and mutations on the one hand and genome-wide 
DNA hypomethylation and region specific hypermethylation on the other hand. 
Furthermore, CLL cells are highly dependent on the interplay with other cells of the 
immune system and the lymphoid tissues, which represents the leukemic 
microenvironment.  
4.1. Prognostic factors characterizing CLL include surrogate markers and 
genetic aberrations and are involved in clonal evolution 
CLL patients can be subdivided into two groups which are categorized by the mutation 
status of the heavy chain variable region (IGHV) of the B-cell receptor (BCR), which is 
either classified as mutated (below 98% homology compared to germline) or unmutated. 
IGHV unmutated patients show poor prognosis in comparison to IGHV mutated cases, 
highlighting the status of the BCR as important predictive marker.222–224 Independent of 
their mutation status, CLL cells are highly dependent on BCR signaling and interestingly 
stereotyped and quasi-identical BCRs were found in different CLL patients.225 Moreover, 
BCRs in CLL cells are able to induce antigen-independent cell-autonomous signaling 
which in line with biased IGHV usage highlights a signal dependency in the 
pathomechanism of CLL.226–228 Although the differences on expression level between 
IGHV mutated and unmutated are relatively low in comparison to CLL vs normal B-cells, it 
is estimated that these subgroups arise from two different B-cell stages of which the origin 
is still under debate. However, a recent study of Seifert et al. indicates that IGHV 
unmutated CLL develops from mature CD5+ B-cells while IGHV mutated CLL could 
originate form distinct, previously unrecognized CD5+CD27+ post-germinal center 
B-cells.229 
Besides IGHV mutation status other predictive markers have been identified in the course 
of CLL and are used for risk stratification in the clinic, the most important including 
expression of ZAP70 and CD38. The expression of the zeta-chain associated protein 
kinase 70 (ZAP70) is tightly associated with IGHV unmutated CLL cases and hence 
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another risk factor with even stronger impact than IGHV mutation status.230,231 If present, 
ZAP70 mediates a more effective BCR signaling in CLL cells, independent of its kinase 
activity, resulting in increased NFκB signaling after BCR stimulation, enhanced response 
to survival signals, higher proliferation rates and increased resistance to apoptosis.232–235 
Similar like ZAP70 the expression of the surface marker CD38 is associated with IGHV 
mutation status and further linked to aggressive clinical behavior, shorter progression free 
and overall survival (PFS, OS).224 However, the abundance of ZAP70 and CD38 can vary 
between disease stages, upon treatment and over time and therefore, are under debate 
as surrogate markers for disease prediction.  
More stable over time, and hence of higher predictive value, are genetic lesions which 
characterize CLL cells and occur in about 80% of patients. Most frequent are deletions in 
13q14, 17p and 11q as well as trisomy 12 (Figure 4).236 In contrast to the other genetic 
aberrations, 13q14 is the only one marking favorable course of disease and besides that 
with an incidence of about 50% the most frequent one. A tumor suppressor gene or 
mechanism is assumed in this region which would be inactivated by deletion in one allele 
and mutation in the other one. In fact, it could be shown that the epigenetic up-regulation 
of the long non-coding RNAs DLEU1 and DLEU2 in 13q14 results in the down-regulation 
of a gene cluster that targets NFκB signaling.237  
 
 
Figure 4. Prognostic impact of chromosomal aberrations in CLL. (A) “Probability of survival from the date 
of diagnosis among the patients in the five genetic categories. (B) Probability of disease progression, as 
indicated by the treatment-free interval in the patients in the five genetic categories.” Modified from Döhner et 
al.236 
The deletion of the chromosomal band 11q22-23, which occurs in about 18% of CLL 
cases, includes the serine threonine protein kinase Ataxia telangiectasia mutated gene 
(ATM) which in addition displays a mutation rate of about 12% in CLL.238 Both, deletions 
and mutations are associated with more rapid disease progression resulting in impaired 
overall and treatment free survival.239 As an important component of the DNA damage 
pathway, ATM is necessary for the induction of apoptosis upon DNA damage and indeed, 
mutations in this gene were shown to vitiate in vitro DNA damage response.238  
17p13 is another chromosomal region frequently deleted in CLL (7%) and affects the 
prominent tumor suppressor gene TP53. Most patients with monoallelic 17p deletion show 
mutations in the remaining TP53 allele and like the other aberrations this deletion is linked 
to poor prognosis and in addition poor response to therapy.240,241 
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NGS techniques have allowed to analyze the CLL genome in more detail. Several studies 
could confirm mutations in TP53 and ATM. In addition, also a panel of previously 
undiscovered mutations where revealed, of which impact and function have yet to be 
investigated, including mutations in MYD88, KLHL6, FBX7, SF3B1, KRAS, BCOR and 
NOTCH1.242–245  
 
Figure 5. Model for the stepwise transformation of CLL. “Earlier (A) and later mutations, B-cell specific (B) 
and ubiquitous cancer events (C and D) drive CLL pathogenesis. Clonal evolution and treatment show 
complex relationship. Most untreated CLLs and minority of treated CLLs maintain stable clonal equilibrium 
over years (C). In presence of a subclone containing a strong driver, treatment may disrupt interclonal 
equilibrium (D).” Modified from Landau et al.243 
Besides the discovery of novel mutations, NGS also led to the extensive analysis of 
another cancer attribute which is clonality and clonal evolution (Figure 5). Whole-exome 
sequencing studies and copy number analysis showed that CLL displays intratumoral 
heterogeneity represented by various numbers and types of sub-clones. Genetic 
aberrations can partly be classified as driver mutations which are predominantly clonal like 
mutations in MYD88, trisomy 12 or 13q deletion, and hence arise early in CLL 
development. Furthermore, they can be subclonal like SF3B1 and TP53 mutations which 
would reflect late events in CLL pathogenesis and possibly contribute to disease 
progression. Especially after treatment, clonal evolution could be observed, reflected by 
the expansion of subclones that harbor driver mutations. It can be assumed that the 
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outgrowth of subclones after treatment results in the observed resistance and relapse of 
the CLL patients and is potentially supported by the microenvironment of the CLL cells.243 
4.2. CLL microenvironment  
In in vitro culture CLL cells undergo rapid and spontaneous apoptosis which can be 
prevented by co-culture with bone marrow stromal cells (BMSCs) or other feeder cells that 
offer survival support.246 Furthermore, CLL cells in bone marrow and lymph nodes show 
up-regulation of activation markers and especially the lymph node microenvironment 
promotes BCR signaling, NFκB activation and tumor proliferation in CLL.247 These findings 
support the notion that CLL cells are highly dependent on their microenvironment. As a 
matter of fact, CLL cells can interact with numerous cell types of the immune system 
including mesenchymal stromal cells, monocyte-derived nurse like cells (NSCs) as well as 
T-cells.248–250  
NLCs and BMSCs protect CLL cells not only from spontaneous but also drug induced 
apoptosis.251–253 Vice versa, CLL cells can activate BMSCs in the patient which in contrast 
to healthy-donor derived BMSCs significantly promote normal B-cell proliferation and IgG 
production.254,255 NLCs differentiate from CD14+ blood monocytes in co-culture with CLL 
cells in high-density conditions and can be found in spleen and lymphoid tissues of CLL 
patients.251,253 Upon co-culture with NLCs, CLL cells showed characteristic induction of 
genes in BCR- and NFκB pathways and production of T-cell attracting chemokines.256 In 
general, CLL patients display increased number, in particular of CD8+ T-cells in the 
peripheral blood, which exhibit profound functional defects like chronic activation and 
exhaustion.257 In addition, these cells show alterations in genes involved in cytoskeletal 
formation and similar defects are induced in healthy T-cells after CLL co-culture.258 
Presumably these changes result in defects in the formation of immunological synapse 
with antigen presenting cells.259 
However, these are just some examples depicting the microenvironmental factors 
impacting on CLL pathogenesis. Recent research focuses on the relations of CLL cells 
with bystander cells and disruption of the supportive interactions is a promising treatment 
strategy. 
4.3. DNA methylation in CLL 
CLL is a disease not only defined by genetic but also by epigenomic aberrations. Similar 
to other cancer types, CLL is known to display global hypomethylation which is strongly 
associated with repetitive sequences like Alu, LINE-1 and SAT-α.260 On the other hand, 
region specific hypermethylation results in the deregulation of a number of CLL prognostic 
genes and tumor suppressors important for CLL pathogenesis (Figure 6).  
These include for example the von Hippel-Lindau gene (VHL), which is preferentially 
methylated and down-regulated in IGHV unmutated CLL. The highly prognostic ZAP70 
shows a small DMR in its 5’ regulatory region which illustrates large variability in DNA-
methylation in CLL cells.261,262 A single CpG unit seems to be important for expression of 
this gene and shows strong association with IGHV mutation, PFS and OS. Moreover, 
DAPK1 is down-regulated through methylation and contributes to heritable predisposition 
in CLL. The oncogene BCL-2 displays hypomethylation and overexpression which is a 
feature of CLL already known for two decades.263,264 WNT signaling activation in CLL is 
related to hypermethylation of WNT inhibitor (antagonist) genes and the key transcription 
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factor of WNT signaling LEF-1.265–267 Besides protein coding genes, aberrant methylation 
in CLL was shown to be associated with abnormal miRNA expression and in addition, 
methylation markers can be used to improve risk stratification even independent of IGHV 
and CD38 expression status.268,269 
 
 
Figure 6. Epigenetic factors shaping the DNA methylome in CLL. “DNA hypermethylation silences tumor 
suppressor genes, DNA hypomethylation leading to genomic instability, dysregulation of epigenetic regulators 
and machinery, interplay between DNA methylation and other epigenetic / microenvironmental factors.” 
Modified from Cahill & Rosenquist270 
Recently, NGS techniques and the application of 450K Illumina Bead Chip methylation 
arrays have allowed to analyze DNA methylation in greater detail. While the genome-wide 
hypomethylation and region specific hypermethylation could be confirmed in several 
studies, it was revealed that methylation patterns are more complex than originally 
thought. Kulis and colleagues analyzed 139 CLL samples with 450K methylation arrays 
and compared these to different non-malignant B-cell subsets.271 A widespread gene-body 
DNA hypomethylation as well as a large proportion of aberrant methylation positioned in 
gene bodies was observed. Correlation of only 4% of CpGs with expression was detected 
and interestingly gene body methylation that correlated with gene expression was related 
to enhancers. Subsequently, three different clinico-biological CLL subgroups could be 
defined classifying CLL samples as NBC-like (naïve B-cell), intermediate or MCL-like 
(mature B-cell) CLL. In addition, this re-classification also confirmed again differential 
methylation between IGHV mutated and unmutated CLL where unmutated CLL was 
closely related to CD5+ NBCs and NBCs and mutated CLLs resembled MBCs.  
Another comparison of IGHV mutated and unmutated CLL cases by Cahill et al. identified 
2239 differentially methylated CpG sites, with the majority outside CGIs but many in CGI 
shores. Numerous CLL relevant genes (e.g. CLLU1, LPL, ZAP70, NOTCH1) as well as 
epigenetic regulators (HDAC9, HDAC4, DNMT3B) and B-cell signaling genes were 
alternatively methylated between the two subgroups. In addition, this study showed that 
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global DNA methylation in CLL is stable over time and similar in resting and proliferative 
compartments.272  
 
 
Figure 7. Proposed interaction between methylation disorder and clonal evolution. “(A) Novel somatic 
mutation has to coincide with an epigenetic state that will be permissive to the propagation of the new 
genotype. In a cellular population with ordered epigenetic state, the proportion of cells that are able to actively 
participate in the evolutionary process is small. In a disordered epigenetic state, a greater proportion of cells 
can give birth to new subclones, increasing diversity and adaptive capacity of cancer population, resulting in 
(B) adverse clinical outcome with therapy.” Modified from Landau et al.2014273 
Of note, NGS identified allele-specific methylation (ASM) within CLL samples which does 
not reflect imprinting but is a result of methylation loss. Only 0.4% of ASM was recurrent 
and potentially disease specific. At the same time CLL cells display lower intrasample 
heterogeneity in comparison to healthy B-cells, but stronger interpatient variability which 
to some degree is a result of locally disordered methylation in the malignant cells.273,274 It 
is assumed that this higher amplitude of epigenetic “noise” allows the cancer cells a 
greater degree of population diversity, which would go in line with the notion of genetic 
evolution described above. In fact, these current results indicate that genetic aberrations 
evolve co-dependently with methylation (Figure 7).274  
 
4.4. NOTCH1 signaling is constitutively active in CLL 
NOTCH1 is one of 4 NOTCH proteins that have been identified so far and are responsible 
for NOTCH signaling, a highly conserved canonical pathway also present in mammals. 
NOTCH1 codes for a single-pass transmembrane protein which harbors an intra- and an 
extracellular domain. The latter allows interaction of NOTCH1 with five different ligands 
(DLL1, DLL3, DLL4, JAGGED1 and JAGGED2) which are consequently able to activate 
NOTCH1 signaling in a cell-cell contact dependent manner.275–277 Ligand-engagement 
results in a series of proteolytic cleavages which leads to release of first the NOTCH1 
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extracellular domain and finally the NOTCH1 intracellular domain (NICD) by the protein γ-
secretase.278 After translocation to the nucleus, NICD acts together with other proteins like 
CSL and MAML1 as transcription factor complex which binds to and activates its down-
stream targets including HES1, CCND1 and KLF4 (Figure 8).279–281 
 
 
Figure 8. NOTCH1 signaling pathway. NOTCH1 activation by its ligands DLL1, 3, 4 and JAGGED1 and 2 
results in cleavage and translocation of the NOTCH intracellular domain (NICD). As transcription factor 
complex together with CSL and MAML1 it can activate a number of downstream targets including HES1, 
CCND1 and KLF4.  
Of note, KLF4 and NOTCH1 are able to co-regulate each other resulting in a potential 
circuitry between NOTCH1 signaling and KLF4 activity. In head and neck cancer 
(HNSCC), NOTCH1 can increase KLF4 activity by direct binding of NICD/CSL to the KLF4 
promoter. NOTCH1-mediated repression of KLF4 expression via up-regulation of HES1 
was shown in intestinal epithelium and T-ALL.282–284 In primary human breast tumors and 
epithelial cells, KLF4 binds to the NOTCH1 promoter and induces its transcription while 
down-modulation of NOTCH1 was observed in keratinocytes.285,286 In these cells, knock-
down of KLF4 and in addition another transcription factor (SP3) was necessary to 
increase NOTCH1 transcription.287 In summary, these findings suggest that NOTCH1 and 
KLF4 can co-regulate each other, however this regulation is highly influenced by other 
factors and hence a potential interplay has to be investigated for each case individually. 
NOTCH1 is supposed to be an oncogenic driver in a number of cancers such as colon 
and breast cancer and T-ALL.288,289 In the latter, NOTCH1 was found to be mutated in 
about 60% of cases.290 Two types of mutations were identified resulting either in a 
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C-terminally truncated NICD or loss of the PEST domain which allows the accumulation of 
NOTCH1 due to abrogated denaturation of the protein.291 Activation of NOTCH1 was 
shown to induce leukemia in murine models of T-ALL and moreover NOTCH1 signaling is 
required for hypoxia-related proliferation and chemoresistance.292,293 Hence, the pathway 
has emerged as promising treatment target and a number of NOTCH1 inhibitors are 
currently under investigation.283,294 
In CLL, NOTCH1 was recently found to be recurrently mutated in 6-12% of patients. 
Similar to T-ALL, most mutations are found in the PEST domain and result in the 
accumulation of a truncated NOTCH1 due to impaired degradation. In these NOTCH1 
mutated cases, NOTCH1 signaling is hence constitutively active and further results in the 
activation of NFκB signaling.295 Besides this mutation mediated activation of this signaling 
pathway, NOTCH1 as well as its ligands JAGGED1 and 2 are highly expressed in CLL 
cells in contrast to normal B-cells.296 In vitro co-culture with BMSCs up-regulates NOTCH1 
and NOTCH1 ligand increases B-CLL survival while blockage of NOTCH1 signaling 
results in increased apoptosis of the cells.296,297 These findings support an important role 
of NOTCH1 signaling activity in the pathomechanism of CLL. Indeed, NOTCH1 mutations 
are associated with shorter overall survival and further, NOTCH1 mutated cases undergo 
transformation into DLBCL (Richter’s transformation) more frequently.242,244,298–300  
4.5. Role of KLF4 in tumorigenesis and B-cell development 
One NOTCH1 target gene is the transcription factor Krüppel-like factor 4 (KLF4) which 
has bivalent functions and can either repress or activate its downstream targets. Initially, 
KLF4 was characterized as one of the four Yamanaka factors which are able to induce 
pluripotent stem cells (iPS) from adult human dermal fibroblasts.301 Since then, KLF4 was 
shown to be important not only for differentiation but also for ESC self-renewal, DNA-
damage induced apoptosis, cell cycle progression and cell proliferation.302–305 
Furthermore, KLF4 is important for monocyte differentiation, required for lineage 
commitment, proliferation and homing of T-cells, acts as mediator of pro-inflammatory 
signaling in macrophages and seems to have a prominent role in B-cell development and 
differentiation.306–309 During B-cell maturation KLF4 expression increases, and naïve 
mature B-cells express higher levels of KLF4 than memory B-cells. Upon activation of 
B-cells via CD40 and BCR signaling, KLF4 is down-regulated. KLF4 overexpression 
maintains the cells in a resting state.310 Moreover, KLF4-deficient mice show decreased 
numbers of pre-B-cells in bone marrow and mature B-cells in spleen, suggesting KLF4 to 
be necessary for regulation of B-cell number and activation-induced B-cell proliferation.311  
In line with its diverse functions, KLF4 was shown to have oncogenic as well as tumor 
suppressive potential. In head and neck as well as breast cancer an oncogenic role of 
KLF4 is assumed, while it was shown to act as tumor suppressor in various other types of 
cancer including urothelial, pancreatic, ovarian and cervical cancer, as well as in several 
B-cell malignancies.303,312–315 In AML CDX2 driven leukemogenesis involves KLF4 
repression and down-regulation of p21.316 In lymphoma cell lines and primary cases of FL, 
DLBCL, BL and classical Hodgkin-lymphoma (cHL) KLF4 was shown to be silenced by 
promoter methylation. Overexpression of KLF4 induced the accumulation of these cells in 
G0 / G1 phase and growth inhibition as well as apoptosis mediated via BAK1.317 Besides, 
the expression of KLF4 in B-cell progenitors of transgenic mice blocks transformation by 
BCR-ABL (Philadelphia chromosome) and depletes leukemic pre-B cells in vitro.318  
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5. Project outline 
Chronic lymphocytic leukemia is one of the most common leukemias in the western world 
and recent work applying NGS has greatly improved our knowledge about this disease. 
However, CLL remains incurable and patients relapse and in addition have to stay under 
permanent treatment. It is therefore necessary to further expand our understanding of the 
pathomechanism of CLL and to identify new treatment targets.  
Aim of this project was the identification of genes deregulated by DNA methylation in CLL, 
as these genes could play a role in CLL development or maintenance. For this purpose, 
RNA and DNA was isolated from CD19+ CLL cells of 15 untreated patients and B-cells of 
9 age-matched healthy donors (Figure 9). While RNA was analyzed on expression arrays, 
DNA was applied to methyl-CpG-immunoprecipitation (MCIp). The highly methylated DNA 
fragments isolated with this method were subsequently analyzed on promoter tiling-arrays 
covering promoter regions -3.8 kb to +1.5 kb around transcription start sites of all RefSeq 
genes.   
 
Figure 9. Project outline. (A) Cohort of 13 CLL patients and 9 age matched healthy donors. (B) Isolation of 
RNA and DNA from CD19+ CLL/B-cells. (C) Methyl-CpG-immunoprecipitation (MCIp) auf DNA samples. (D) 
Expression and promoter-array analysis of RNA and DNA. (E) Identification of genes with significantly 
correlating aberrant expression and DNA methylation.  
Data of MCIp- and expression arrays were analyzed in an integrative approach searching 
for genes which display differentially methylated regions within their promoters and 
concurrent correlating, aberrant expression between CLL and B-cells. Genes identified to 
be potentially deregulated in CLL by DNA methylation were validated in their methylation 
with mass spectrometry based methylation analysis (MassARRAY) and concerning their 
expression  with quantitative real-time PCR (qRT-PCR). Finally, potential candidate genes 
were functionally characterized in the course of CLL, to reveal their impact on disease 
pathogenesis. 
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II. Material and methods 
1. Materials 
1.1. Instruments 
Instrument Supplier 
ABI PRISM 3100 Genetic Analyzer Life Technologies, Darmstadt, Germany 
ABI PRISM 7900HT Fast RealTime PCR System Life Technologies, Darmstadt, Germany 
Agilent 2100 Bioanalyzer Agilent, Santa Clara, USA 
Agilent Technologies Scanner G2505C 
US81503234 Agilent, Santa Clara, USA 
Amaxa Nucleofector 2b device Lonza, Basel, Switzerland 
BD FACSCanto II BD Biosciences, San Jose, USA 
Bioruptor Diagenode, Lüttich, Belgium 
Eppendorf PCR Cycler (Mastercylcer Gradient) Eppendorf, Hamburg, Germany 
MassARRAY Analyzer 4 System Sequenom, San Diego, USA 
MassARRAY Nanodispenser Sequenom, San Diego, USA 
Matrix Equalizer Electronic Multichannel Pipettes Thermo Fisher Scientific, Waltham, USA 
Mini Protein Gel Transfer System BioRad, Munich, Germany 
Mithras LB 940 Plate Reader Berthold Technologies, Bad Wildbad, Germany 
NanoDrop ND-1000 spectrophotometer NanoDrop, Wilmington, USA 
Photometer Bio Eppendorf Eppendorf, Hamburg, Germany 
ViCell XR cell counter Beckman Coulter, Krefeld, Germany 
XCell SureLock Mini-Cell Electrophoresis System Life Technologies, Darmstadt, Germany 
 
1.2. Reagents and consumables 
Reagent / Consumable Supplier 
1.5 / 2 ml Safe-Lock Tubes Eppendorf, Hamburg, Germany 
15 / 50 ml BD Falcon tubes BD Biosciences, San Jose, USA 
200x S-adenosyl methionine NEB, Frankfurt am Main, Germany 
7AAD BD Biosciences, San Jose, USA 
ABgene Superplate 96-well Plate Thermo Fisher Scientific, Waltham, USA 
Absolute SYBR Green ROX Mix Abgene, Epsom, UK 
Ampicillin Roche Diagnostics, Mannheim, Germany 
Annexin-V binding buffer 10x BD Biosciences, San Jose, USA 
Annexin-V FITC BD Biosciences, San Jose, USA 
Biocoll Biochrom, Berlin, Germany 
Bovine serum albumin Sigma-Aldrich, Munich, Germany 
Cell culture dish (6-well, 12-well, 24-well) TC-plate 
suspension F Sarstedt, Nümbrecht, Germany 
Cell culture flasks TC-flask suspension (T25, T75, 
T175) Sarstedt, Nümbrecht, Germany 
CpG Methylated Human Genomic DNA Thermo Fisher Scientific, Waltham, USA 
DMEM medium (4.5 g/L glucose) Sigma-Aldrich, Munich, Germany 
DMSO  Sigma-Aldrich, Munich, Germany 
dNTP set PCR grade 100 mM each Roche Diagnostics, Mannheim, Germany 
ECL (plus) WB Detection Reagents GE Healthcare, Munich, Germany 
Ethanol Sigma-Aldrich, Munich, Germany 
Fetal calf serum (FCS) Biochrom AG, Berlin, Germany 
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Formamide Merck Millipore, Darmstadt, Germany 
Fuji X-ray Film Super RX, 18x24 cm Fujifilm, Tokio, Japan 
Gamma secretase inhibitor I Merck Millipore, Darmstadt, Germany 
GeneRuler DNA Ladder Mix Life Technologies, Darmstadt, Germany 
Human Cot-1 DNA Invitrogen, Karlsruhe, Germany 
Human type AB serum, heat inactivated MP Biomedicals, Eschwege, Germany 
Immobilon-P PVDF membrane Merck Millipore, Darmstadt, Germany 
Leucosep tubes 50 ml Greiner Bio-One, Kremsmünster, Austria 
MACS CD19 Micro Beads Miltenyi Biotech, Bergisch Gladbach, Germany 
Matrix pipette tips 384 125 µl Thermo Fisher Scientific, Waltham, USA 
MBD2-Fc Protein Provided by Dieter Weichenhan (DKFZ) 
NuPAGE Antioxidant Life Technologies, Darmstadt, Germany 
Nunc F96 MicroWell White Polystyrene plate (white) Thermo Fisher Scientific, Waltham, USA 
NuPAGE Novex 3-8% Tris-Acetate Protein Gels Life Technologies, Darmstadt, Germany 
NuPAGE Novex 4-12% Bis-Tris Protein Gels Life Technologies, Darmstadt, Germany 
NuPAGE sample Reducing Agent (10x) Life Technologies, Darmstadt, Germany 
NuPAGE SDS Running Buffer (20x) Life Technologies, Darmstadt, Germany 
NuPAGE SDS Sample Buffer (4x) Life Technologies, Darmstadt, Germany 
NuPAGE Tris-Acetate SDS Running Buffer (20x) Life Technologies, Darmstadt, Germany 
PageRuler Prestained Protein ladder Life Technologies, Darmstadt, Germany 
Penicillin/Streptomycin (1000U/ml) Life Technologies, Darmstadt, Germany 
Qiashredder Qiagen, Hilden, Germany 
RNase free water Qiagen, Hilden, Germany 
RPMI 1640 media Sigma-Aldrich, Munich, Germany 
SIMAG Protein A/G Chemicell, Berlin, Germany 
Skim Milk Powder Sigma-Aldrich, Munich, Germany 
Spectra Multicolor Broad Range Protein Ladder Life Technologies, Darmstadt, Germany 
Spectro Chips II Sequenom Inc., San Diego, USA 
TMAC (tetramethylammonium chloride solution) Sigma-Aldrich, Munich, Germany 
Tween20 Sigma-Aldrich, Munich, Germany 
Universal Human Reference RNA Agilent, Santa Clara, USA 
 
1.3. Cell lines and bacteria 
Characteristics Supplier 
GRANTA-519 cell line 
B-cell lymphoma; established from the peripheral blood from a 58-year old 
Caucasian woman with high-grade NHL (non-Hodgkin lymphoma) at 
relapse (leukemic transformation of mantle cell lymphoma, stage IV); 
previous history of cervical carcinoma 
DSMZ, 
Braunschweig, 
Germany 
JeKo-1 cell line 
B-cell lymphoma; established from peripheral blood of 78-year old female 
with MCL (Mantle Cell Lymphoma) 
ATCC, Manassas, 
USA 
LCL-FM cell line 
B-lymphoblastoid cells; spontaneous developed cell line (WT EBV) from 
a patient with history of mamma-carcinoma and angiosarcoma 
provided by Silke 
Brüderlein (Ulm) 
LCL-MM cell line 
B-lymphoblastoid cells; established from peripheral blood of MCCL 
(mediastinal clear-cell lymphoma) patient; EBV transformation 
provided by Silke 
Brüderlein (Ulm) 
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LCL-WEI cell line 
B-lymphoblastoid cells; established from peripheral blood of male patient 
with melanoma; EBV transformation 
DSMZ, 
Braunschweig, 
Germany 
MEC1 cell line 
Chronic B-cell leukemia; established from peripheral blood of a 61-year 
old Caucasian man with CLL in prolymphocytoid transformation to B-PLL; 
serial sister cell line of MEC2 
DSMZ, 
Braunschweig, 
Germany 
MEC2 cell line 
Chronic B-cell leukemia; established from peripheral blood of  a 62-year 
old Caucasian man with CLL in prolymphocytoid transformation to B-PLL 
prior to therapy; serial sister cell line of MEC1 
DSMZ, 
Braunschweig, 
Germany 
OneShot TOP10 chemically competent E.coli 
Genotype: F- mcrA ∆( mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆ lacX74 
recA1 araD139 ∆( araleu)7697 galU galK rpsL (StrR) endA1 nupG 
Life Technologies, 
Darmstadt, Germany 
 
1.4. Kits 
Kit Supplier 
Absolute QPCR SYBR Green ROX mix Thermo Fisher Scientific, Waltham, USA 
Agilent aCGH Hybridization Kit Agilent, Santa Clara, USA 
AllPrep DNA/RNA Mini Kit Qiagen, Hilden, Germany 
BigDye Terminator v3.1 Cycle Sequencing Life Technologies, Darmstadt, Germany 
BioPrime Total Genomic Labeling System Invitrogen, Karlsruhe, Germany 
CellTiter-Glo Luminescence cell Viability Assay Promega, Madison, USA 
EndoFree Plasmid Maxi Kit Qiagen, Hilden, Germany 
EpiTect 96 Bisulfite Kit (2) Qiagen, Hilden, Germany 
EpiTect Bisulfite Kit (48) Qiagen, Hilden, Germany 
EpiTect Fast Bisulfite Kit (2) Qiagen, Hilden, Germany 
Gateway LR ClonaseII Enzyme mix Life Technologies, Darmstadt, Germany 
Genomic DNA Enzymatic Labeling Kit Agilent, Santa Clara, USA 
MassCLEAVE Kit Sequenom, San Diego, USA 
MinElute PCR Purification Kit Qiagen, Hilden, Germany 
Nucleofector Kit V Lonza, Basel, Switzerland 
Oligo aCGH/ChIP-on-Chip Wash Buffer Set Agilent, Santa Clara, USA 
Plasmid Mini Kit Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
QuantiTect Reverse Transcription Kit Qiagen, Hilden, Germany 
REPLI-g Kit Qiagen, Hilden, Germany 
RNA 6000 Nano Kit Agilent, Santa Clara, USA 
RNeasy Micro kit Qiagen, Hilden, Germany 
RNeasy Mini kit Qiagen, Hilden, Germany 
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1.5. Buffers and solutions 
Buffer Reagents 
10x PBS (Phosphate-buffered 
saline) 
10 mM KH2PO4, 155 mM NaCl, 30 mM Na2HPO4-7H2O, 
pH7.4 
10x TBE (Tris-borate-EDTA) 89 mM Tris, 89 mM boric acid, 2 mM EDTA 
10x TBS (Tris-buffered saline) 50 mM Tris, 150 mM NaCl, pH7.6 
10x TME 200 mM Tris/HCl pH8.0, 20 mM MgCl2, 5mM EDTA pH8.0 
Buffer A (MCIp, low salt) 1x TME, 0.3 M NaCl, 0.1% NP40 
Buffer B (MCIp) 1x TME, 0.4 M NaCl, 0.1% NP40 
Buffer C (MCIp) 1x TME, 0.5 M NaCl, 0.1% NP40 
Buffer D (MCIp) 1x TME, 0.55 M NaCl, 0.1% NP40 
Buffer E (MCIp) 1x TME, 0.6 M NaCl, 0.1% NP40 
Buffer F (MCIp, high salt) 1x TME, 1 M NaCl, 0.1% NP40 
FACS buffer 1x PBS, 5% FCS, 1% BSA, 0.05% NaAzid 
LB-agar 10g Bacto Trypton, 5g yeast extract, 10g NaCl, 15 g Agar, adjust to 1l with ddH2O 
LB-medium 10 g Bacto Trypton, 5 g yeast extract, 10 g NaCl, adjust to 1l with ddH2O 
PBS-T 1x PBS, 0.1% Tween20 
RIPA (Radio-Immunoprecipitation 
Assay buffer ) 
150 mM NaCl, 1.0% IGEPAL; 0.5% sodium deoxycholate, 
0.1% SDS, 50 mM Tris, pH8.0 
TBS-T 1x TBS, 0.1% Tween20 
10x Western Blot buffer  1.92 M Glycine, 0.25 M Tris 
 
1.6. Antibodies 
Antibody Source Supplier 
Anti-KLF4 (H-180) rabbit Santa Cruz, Dallas, USA 
Anti-GAPDH (6C5) mouse Merck Millipore, Darmstadt, Germany 
Anti-NOTCH1 (mN1A) mouse Abcam, Cambridge, UK 
Anti-CD20-PE (2H7) mouse BD Biosciences, San Jose, USA 
Anti-CD19-APC (HIB19) mouse BD Biosciences, San Jose, USA 
Anti-CD5-FITC (L17F12) mouse BD Biosciences, San Jose, USA 
anti-mouse IgG HRP-linked  horse Cell Signaling Technology, Danvers, USA 
anti-rabbit IgG HRP-linked goat Cell Signaling Technology, Danvers, USA 
 
1.7. Enzymes  
Enzyme Supplier 
HotStarTaq DNA Polymerase (1u/µl) Qiagen, Hilden, Germany 
PRECISOR High-Fidelity DNA Polymerase BioCat, Heidelberg, Germany 
T4 DNA Ligase (1 U/µl) Life Technologies, Darmstadt, Germany 
NotI (10,000 U/ml) Life Technologies, Darmstadt, Germany 
HindIII (10,000 U/ml) Life Technologies, Darmstadt, Germany 
CpG Methyltransferase (M.SSsI; 20 U/µl) NEB, Frankfurt am Main, Germany 
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1.8. Primers 
qRT-PCR 
Gene Forward (5' to 3') Reverse (5' to 3') 
BAK GGTCCTGCTCAACTCTACCC CCTGAGAGTCCAACTGCAAA 
BAX GCTGGACATTGGACTTCCTC GTCTTGGATCCAGCCCAAC 
BCL-2 AAAAATACAACATCACAGAGGAAGT GCGGAACACTTGATTCTGGT 
CCND1 AACTACCTGGACCGCTTCCT GCTCCATTTGCAGCAGCTC 
HES1 AGAAAGATAGCTCGCGGCATT TACTTCCCCAGCACACTTGG 
HPRT TGTAGCCCTCTGTGTGCTCAAG CCTGTTGACTGGTCATTACAATAGCT 
KLF4 GCGGCAAAACCTACACAAAG CGTCCCAGTCACAGTGGTAA 
LILRA4 ATTCCAAGACTGCCCCACAC TGCGGATGAGATTCTCCACT 
MCL-1 TAAGGACAAAACGGGACTGG CCAGCTCCTACTCCAGCAAC 
NOTCH1 CTGAAGAACGGGGCTAACAA CAGGTTGTACTCGTCCAGCA 
NOXA GCTGGAAGTCGAGTGTGCTA CCTGAGCAGAAGAGTTTGGA 
PGK AAGTGAAGCTCGGAAAGCTTCTAT TGGGAAAAGATGCTTCTGGG 
 
MassARRAY 
 5'-tag forward primer AGGAAGAGAG 
 5'-tag reverse primer CAGTAATACGACTCACTATAGGGAGAAGGCT 
   
Gene Forward (5' to 3') Reverse (5' to 3') 
ADRB2 GAGTTTGTTGATTAAGAATAAGGTT CAAAAAATAAAAATACCCATAATAATA 
ADRM1 TTGGTTTTTGTATATTTGGTTTTTG TTTTAAAAAATATAACCACTTTTCATTTTA 
BCKDK GAGTTTGGGGTTTAGAGTGGTAGA AATCACCACATCCTTATAATCATCC 
C19ORF12 TATGGAAAAATGAGTTAGATATGGTTG TTCCCAAATAAAAAAACTAAAACAC 
C21ORF33 TGATGATATTAGGTGTTTTGTGGTT CTAACCCTCTTCAAACTTCTCAACT 
CBX7 GGAAAAGGTTAAAGTTTAGTAGGAAAAAT ACTCCCAAAACCCCAATAAAAT 
CORO1B TTTTGTTGGTTTTATTGTTGGTTTT CACCCCTACTAAACCTTTCTACACA 
CXCR3 GGTTTATTTGTGGGAAGTTGTATTG CCCTCCTAAAAAACTTCAACTCTT 
CYB5R3 TTTTTTTGTTTTGTTTTTTTGGTAG CTCATACCTATAATCCCAATACTCC 
EPRS AGTTTAGGAAGATGAGGTTGTAGTG AAAAAATATAATCTAAAAAACCCTC 
EXOSC3 TTTTAAATTTTTAATTTTAAATGATT ACTTAACAAAAAAATAACAACAAAC 
FKBP3 TTTATTAAAATGGGGTAAGATTTT ATTACCCAAACTAAAATACAATAAC 
GRSF1 TTTGGTTAATATGGTGAAATTGTGTT AAACTCCAATAATCCTCTCACTTCA 
HGS GTGGGAGGGTTTGGATTAGTATT AACCCATACAATTCTCCACATAAAA 
KLF4 GAGAATAAAGTTTAGGTTTAGGAGAT ATAACAACAAAAAACCACCACTAAC 
LILRA4 MA1 GTTAGGAGGGAGGGTTTTTTAGATA ACCATAAAAAATTCCAAACCCTATT 
LILRA4 MA2 GGGATGTTTTAATTGATTAAGGTATG CACCTTAACCTCCCAAAATACTAAA 
LILRA4 MA3 TTTTTTGTGTGTGTGTGAAAAATAG ACTCCTAACCTCAAATAATCTACCC 
MAFB GTTGTTTTATTTGTTGAATGAGTTG TAAACATAAAACCAAAACTACCCAC 
MBP TTTATGGTATTTGTTGTGGTTAGGTATT CTCTACATACTCAAATAACTTCATC 
NOTCH1 GTTTAGGGTTTGGAGATTTTTTTT ATAATACCCCCATTTCTCTAACAAC 
PSMB10 TTGGTTTTAAATTTTTGAGTTTAGGT TAAAATCCCACACTAAATTTCACTC 
PTBP1 GGGTTTTAGATGTTTTTATTTTTTTT CTTTCTTTAAAACCACCTCTCAAC 
PTPLAD1 TTGAGGTAGAAGAAAGGTATGAATT CAACATCTTTATAACCTCAAACTCC 
SCYL1 TTGGTTATTTATTTTTGTTTTTTTT ATATAATCCAAACCCCCAAACTT 
SEPX1 AAGGAGAGGTAAATGTGGAGTTATTAGT CAACAAAAAAAACCACTTAAAAAAAA 
TCF25 ATTTATAGGGGTAGGAGGTGTGATT AATAAAAATACAAACCAAAAAATCC 
TRAPPC2L GTGGTTTTTAGGAGAAGGTGAGAG AAACCCAAATACAACTCCCTCTAAT 
TSPYL5 GAGATTTTGGTATTGTGAAGGGTT AAATCCCTCAACAAAAATATTCAAA 
UFSP2 AGTTTAGAAGAAAGGTTTAATTTAGAGATA CCTAAAAAAAACTAATCCTACC 
VKORC1 GGTGGAATTAGGTTAGGATTGTTAAT CCAACCTAACCAACATAATAAAAAC 
ZFP90 GAAGATGTAAATGTTTTATTTTTTGA AAAACTACCCAAAAAAACCTCAAC 
ZFYVE21 GTTAAAGTAGTATTAATTGATTGGGTTTAT AAAACCTCTACCTCATCTTAACCAC 
 
 28 Material and methods 
Cloning 
Gene Forward (5' to 3') Reverse (5' to 3') 
KLF4 TTTAAGCTTATGAGGCAGCCACCTGGCGAGTCT TTTGCGGCCGCTTAAAAATGCCTCTTCATGTGTAA 
 
Sequencing 
Target Forward (5' to 3') Reverse (5' to 3') 
T7seq TAATACGACTCACTATAGGG - 
BGHseq - TAGAAGGCACAGTCGAGG 
CMVseq GTGTACGGTGGGAGGTCTAT - 
 
MCIp Control 
Gene Forward (5' to 3') Reverse (5' to 3') 
SNRPN TACATCAGGGTGATTGCAGTTCC TACCGATCACTTCACGTACCTTCG 
MCctF1/R3 GGTTCTCTGCTGCCTTGC CTGAGAAGGGCGAATACGAA 
ZAP70 CAGCTGGACAACCCCTACAT CGACCAGGAACTTGTGCAG 
 
1.9. Plasmids 
Name Insert Supplier 
pDEST26 - Genomic and Proteomics core facility, DKFZ 
pcDNA3.1/V5-His - Life Technologies, Darmstadt, Germany 
pcDNA3.1-KLF4 KLF4  - 
pmaxGFP GFP Lonza, Basel, Switzerland 
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2. Methods 
2.1.  Collection and purification of patient and healthy donor samples 
Peripheral blood from CLL patients was collected with informed written consent (Ethics 
Committee, University of Ulm, approval no.96/08). Buffy coats generated from blood of 
healthy donors were retrieved from the German Red Cross (DRK) in accordance to the 
declaration of Helsinki. Peripheral blood mononuclear cells were isolated by density 
centrifugation in Biocoll (Biochrom) separation solution. Blood was diluted 1:2 with PBS 
and 30 ml centrifuged 20 min at 2200 rpm without brake in a leukosep tube (Greiner Bio-
One) containing 15 ml Biocoll. PBMCs were washed two times with 50 ml PBS and 
viability determined with a ViCell XR cell counter. PBMCs were either directly applied to 
treatment or CD19+ magnetic selection or frozen in culture medium (see II.2.2) 
supplemented with 10% DMSO. CD19+ B-cells and CLL cells were isolated via positive 
magnetic selection using CD19+ Micro Beads (Miltenyi Biotec) as described by the 
manufacturer. Purity of PBMCs and CD19+ sorted cells was determined by flow cytometry 
analysis using anti-CD5-FITC, anti-CD20-PE and anti-CD19-APC antibodies (BD 
Biosciences). Briefly, after washing two times with PBS, up to 1.0 x 106 cells were stained 
in 100 µl FACS buffer with 5 µl of the respective antibody for 30 min at 4°C. Cells were 
centrifuged for 5 min with 1200 rpm and washed two times with 1 ml FACS buffer by 
centrifugation and finally resuspended in 200 µl FACS buffer for measurement on a BD 
FACSCanto II (BD Bioscience).  
2.2.  Cell culture conditions of cell lines and primary CLL cells 
Cell lines MEC1, MEC2 and GRANTA-519 were cultured in DMEM (Sigma-Aldrich) with 
10% FCS (Biochrom) and 1% Penicillin / Streptomycin (Life Technologies) at 37°C and 
5% CO2. The cell lines LCL-FM, LCL-MM, LCL-WEI and JeKo-1 were cultured in RPMI 
(Sigma-Aldrich) with 20% FCS and 1% Penicillin / Streptomycin (Life Technologies) at 
37°C and 5% CO2. All cell lines were splitet every 2 to 4 days and cultured at a density of 
1.0 x 106 to 2.5 x 106 cells/ml. PBMCs from CLL patients were cultured in DMEM (Sigma-
Aldrich) with 10% FCS and 20% human type AB serum (MP Biomedicals) at 37°C and 5% 
CO2 with 2.0 x 106 to 5.0 x 106 cells/ml. 
2.3. Transfection of leukemia cell lines 
For transfection of the cell lines MEC1, MEC2 and JeKo-1 an Amaxa Nucleofector 2b 
device (Lonza) was used for electroporation of the cells. Cell lines were seeded 24h prior 
nucleofection with a density of 1.5 x 106 cells/ml in 40 ml in T175 flasks. Shortly before 
transfection, cells were washed one time with PBS and 1.0 x 107 cells resuspended in 
100 µl nucleofector solution and 2 µg plasmid added per reaction. Nucleofector solution V 
(Lonza) and program X-001 were used for electroporation in the supplied cuvettes. After 
transfection 500 µl of the respective pre-warmed culture medium were added to the 
cuvettes and all cells transferred to 24-well culture plates containing 1.5 ml pre-warmed 
medium. Cells were cultured 3h to 48h at an initial cell density of 2.0 x 106 cells/ml at 37°C 
and 5% CO2. During this culture period splitting of the cells was not necessary. Culture 
medium used for each cell line resembled standard medium as described in II.2.2. For 
each experiment nucleofection with empty vector, without DNA (mock) as well as 
untreated cells were included as control. Upon harvest, 50 µl (about 1.0 x 106 cells) were 
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used for apoptosis analysis using Annexin-V / 7AAD flow cytometry (see II.2.6). 
Remaining cells were washed two times with PBS and for each time point one pellet for 
RNA and one pellet for protein analysis was frozen and stored on -80°C or directly applied 
to sample preparation as described in II.2.5. 
2.4. GSI-I treatment of cell lines and PBMCs from CLL patients 
Cell lines and PBMCs isolated from CLL patient samples were treated for 24h with 2.5 µM 
and 5 µM GSI-I, respectively. Untreated cells and cells treated with 0.002% DMSO were 
the controls. Cell lines were seeded 24h prior treatment at a density of 1.5 x 106 cells/ml in 
40 ml in T175 flasks under standard culture conditions. Treatment was performed in 
duplicates in 12-well plates with 2 ml of 1.0 x 106 cells/ml at 37°C and 5% CO2. After 24h, 
50 µl of the cell solution were used for CellTiter-Glo® Luminsescent Viability assay as 
described in II.2.6. Rest of the cells was washed two times with PBS and half of the cells 
applied to RNA the other half to protein analysis as described below. PBMCs of CLL cells 
were treated at a cell density of 5.0 x 106 cells/ml for 24h at 37°C and 5% CO2. 2ml of the 
cells were seeded in 24-well plates for the treatment under culture conditions described in 
II.2.2. In case of frozen PBMCs from CLL patients, cells were thawed rapidly on 37°C and 
after washing with 10 ml cell culture medium, cultured for 3h to 4h on 37°C prior to 
treatment, to allow adjustment of the cells. After treatment 150 µl cells were used for 
apoptosis measurement with Annexin-V / 7AAD flow cytometry as described below. Rest 
of the cells was washed with PBS two times and applied to protein and RNA analysis (see 
II.2.5).  
2.5. RNA, DNA and protein isolation 
For isolation of DNA, RNA and protein, cells were washed two times with PBS. Pellets 
were either frozen in liquid nitrogen and stored on -80°C or directly lysed in 350 µl buffer 
RLT (Qiagen) and homogenized using QIAshredder (Qiagen) for RNA or DNA isolation. 
DNA and RNA was than isolated according to the manufacturer’s instructions using either 
the AllPrep DNA/RNA Mini or the RNeasy Mini and Micro kits (Qiagen). RNA and DNA 
concentrations were measured on a NanoDrop ND-1000 Spectrophotometer (NanoDrop). 
For expression array analysis RNA quality was assessed by running a RNA 6000 Nano 
Chip (Agilent) on an Agilent 2100 Bioanalyzer (Agilent) as described in the manufacturer’s 
protocol. 
For protein isolation, freshly harvested cells or frozen pellets were resuspended in 20 µl to 
50 µl 1x RIPA by pipetting and incubated on ice for 20 min. Samples were centrifuged with 
full speed for 5 min and supernatant was used as protein lysate for western blot. Protein 
quantification was done with 5 µl of each sample using the Pierce BCA assay (Life 
Technologies) as described in the manufacturer’s manual using 1xRIPA as blank and 
performing measurement on a Mithras LB 940 Plate Reader (Berthold Technologies).  
2.6. Determine cell viability 
To determine cell number and cell viability of cell lines in everyday cell culture, a ViCell 
XR cell counter (Beckman Coulter) was used. For transfection and GSI-I treatment 
experiments, cell viability was determined either with the CellTiter-Glo® Luminescence 
cell Viability Assay (Promega) or by Annexin-V / 7AAD flow cytometry. For CellTiter-Glo 
50 µl of cell solutions together with 200 µl CellTiter-Glo solution were incubated in white 
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96-well plates, on room temperature, for 20 min, with 200 rpm on an orbital shaker. 
Luminescence was measured on a Mithras LB 940 Plate Reader (Berthold Technologies) 
for 0.1 seconds. For Annexin-V / 7AAD flow cytometry up to 1.0 x 106 cells were washed 
two times in PBS and stained in a total volume of 30 µl containing 24 µl 1x Annexin-V 
staining buffer, 3 µl Annexin-V-FITC and 3 µl 7AAD (BD Bioscience) for 30 min on 4°C. 
150 µl Annexin-V staining buffer was added and cells measured on a BD FACSCanto II 
device (BD Bioscience). Annexin-V-FITC and 7AAD double negative cells were 
considered as living cell population.  
2.7. Western Blot 
For western blot analysis cells were lysed with 1xRIPA as described in II.2.5 and 5 µg to 
30 µg of protein was denatured with 2.5 µl NuPAGE SDS sample buffer and 1 µl NuPAGE 
sample Reducing Agent (Life Technologies) per 10 µl protein lysate in a heat block for 
10 min at 70°C. Protein was than separated by electrophoresis with SDS PAGE on 
NuPAGE Novex 4-12% Bis-Tris or 3-8% Tris-Acetate Protein Gels for 45 min to 60 min 
with 150 V to 200 V in 1xNuPAGE Running Buffer in the XCell SureLock Mini-Cell 
Electrophoresis System (Life Technologies). Of Spectra Multicolor Broad Range or 
PageRuler Prestained Protein ladder (Life Technologies) 10 µl were loaded on each gel 
for size estimation of detected proteins. After separation, proteins were transferred onto a 
PVDF membrane (Merck Millipore) in a Mini Protein Gel Transfer System (BioRad) by wet 
blotting procedure in Western Blot buffer. Stepwise increasing current (200 mA 10 min, 
300 mA 10 min, 400 mA 10 min, 500 mA 10 min) was used for the transfer. Subsequently, 
PVDF membranes were blocked in TBS-T with 5% milk powder (Sigma-Aldrich) for 1h at 
room temperature. For primary detection antibodies, incubations were performed in 3 ml 
TBS-T with 5% milk in 50 ml falcon tubes at 4°C over night with constant rolling. HRP-
coupled secondary antibodies were incubated for 1h at room temperature. Anti-NOTCH1 
and anti-KLF4 antibodies were diluted 1:500, anti-GAPDH 1:25,000 for incubation. 
Secondary HRP-coupled antibodies were diluted 1:3,000. In between and after incubation 
steps, membranes were washed three times with TBS-T for 5 min with moderate shaking. 
Chemiluminescent signal detection was performed with ECL (plus) WB Detection 
Reagents (GE Healthcare) and X-ray films (FUJIFilms) as described in the manufacturer’s 
protocol. Exposure time was individually adjusted.  
2.8. Methyl-CpG-immunoprecipitation (MCIp) 
MCIp was performed by Angela Garding and is also described in greater detail in her 
thesis.319 This method was originally developed in the group of Michael Rehli to detect 
global hypermethylation in CpG islands. With this approach methylated DNA is 
precipitated by binding of a recombinant MBD2-Fc fusion protein containing a methyl-
binding domain.320 
For MCIp 2 µg genomic DNA of T-cells or CD19+ B-cells and CLL cells was pushed 10x 
through 22G needles and further shared with ultrasonication in a Bioruptor (Diagenode, 2x 
30 pulses, 24s, 10% amplitude) to obtain fragment sizes of 400 to 500 bp. The shared 
genomic DNA was mixed in a molar ratio of 1:1 with spike DNA (630 bp artificial 
A.thaliana sequence) which was later used to test for enrichment.  
MBD-Fc fusion protein was coupled to SIMAG protein A magnetic beads (Chemicell). To 
do so 40 µl beads were washed one times with 200 µl TBS. 30 µg MBD-Fc protein was 
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added to the beads in a total volume of 200 µl TBS and rotated for 3h on 4°C to allow 
binding. Beads were washed two times with buffer A (low salt) and DNA was added to the 
beads in a final volume of 250 µl buffer A. After rotation for 3h at 4°C supernatant was 
taken off and represents eluate A (low salt fraction), which than contained unmethylated 
DNA that was not bound by the MBD-Fc fusion protein. Beads were washed with buffers 
B to F each two times with 125 µl to obtain 250 µl eluate per wash buffer. Eluate F (high 
salt buffer) should contain highly methylated DNA and was later used for array 
hybridization and analysis. All fractions were desalted using the MinElute Reaction 
Cleanup Kit (Qiagen) as described in the manual. 
Finally, qRT-PCR was performed to control for successful enrichment of methylated DNA. 
Primers used were for ZAP70 which is known to be highly methylated in CLL, SNRPN an 
imprinted gene that shows 50% methylation in humans and the artificial 630 bp fragment 
spike DNA. Enrichment of highly methylated DNA in the high salt fraction and of 
unmethylated DNA in the low salt fraction could be confirmed for all samples used for 
array hybridization. 
2.9. Expression arrays of CD19+ B-cells and CLL cells 
For expression array analysis 0.5 µg RNA of primary samples was checked for sufficient 
quality on an Agilent Bioanalyzer using the Agilent RNA 6000 Nano Kit as described in the 
manual of the kit. Expression array analysis was further performed by the Genomics and 
Proteomics Core Facility of the DKFZ with HumanHT-12v4 Illumina BeadChip Sentrix 
arrays according to the manufacturer’s instructions. 
2.10. Promoter tiling-arrays (MCIp-analysis) 
For methylation analysis, MCIp samples were hybridized onto custom designed 
(eARRAY, Agilent) promoter arrays (2527020 G4125A Human custom CGH microarray 
4x180K) covering -3.8 to +1.8 kb from the TSS of human RefSeq genes. For array 
hybridization MCIp samples from CD19+ B-cells and CLL cells were labeled with Cy5, 
MCIp samples from healthy T-cell pool with Cy3. Labeling was performed with the 
BioPrime Total Genomic Labeling System (Invitrogen) as described by the manufacturer. 
Sample hybridization was performed according to protocol number G4170-90012 for 
Agilent Microarray Analysis of Methylated DNA Immunoprecipitation version 1.0. Read out 
of arrays was done with an Agilent Technologies Scanner G2505C US81503234. 
2.11. Expression arrays of cell lines after KLF4 overexpression 
To analyze effects of KLF4 on its downstream targets, cell lines MEC1, MEC2 and JeKo-1 
were transfected with pcDNA3.1-KLF4 as described in II.2.3. Samples were taken 3h and 
10h after nucleofection and RNA applied to expression array analysis as described in 
II.2.9. 
2.12. Sanger Sequencing 
Sequencing of PCR products and plasmids was performed with the BigDye 
Terminator v3.1 Cycle Sequencing Kit (Life Technologies). 100 to 500 ng of DNA was 
used as template and assembled with 1 µl BigDye, 2 µl sequencing primer (1 µM), 2 µl 
BigDye 5x sequencing buffer and H2O to a final volume of 10 µl. Cycle sequencing was 
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performed in a Eppendorf PCR Cycler (Eppendorf) for 25 cycles as follows: initial 
denaturation at 96°C for 3 min, denaturation at 96°C for 30 sec, primer annealing at 51°C 
for 15 sec and extension at 60°C for 4 min. PCR products were purified by ethanol 
precipitation. 1 µl 3 M sodium acetate and 26 µl ethanol (Sigma-Aldrich) were added and 
centrifuged at 4°C for 30 min at full speed. Precipitated DNA was washed once with 70% 
ethanol, air dried at room temperature and resuspended in 10 µl formamide (Merck) and 
sequenced using an ABI PRISM 3100 Genetic Analyzer (Life Technologies).  
2.13. cDNA synthesis 
For the production of cDNA the QuantiTect Reverse Transcription Kit (Qiagen) was used. 
0.5 to 1 µg of RNA was used for cDNA synthesis per reaction as described in the 
manufacturer’s manual. For qRT-PCR analysis cDNA was diluted 1 to 4 with H2O and 2 µl 
per reaction used as template. 
2.14. Quantitative real time PCR (qRT-PCR) 
qRT-PCR was used to measure gene expression in cell line samples, primary samples 
from CLL patients and normal B-cells. In addition, it was used for quantification of control 
genes and spike DNA in MCIp samples. cDNA was diluted 1 to 4, MCIp samples 1 to 10 
and 2 µl template were used per reaction together with 6 µl ABsolute SYBR Green ROX 
Mix (Thermo Scientific), 0.12 µl of each forward and reverse primer (10 µM) and 3.76 µl 
H2O. Samples were amplified on an ABI PRISM 7900HT Fast RealTime PCR System 
(Life Technologies) for 40 cycles as follows: protein activation and initial denaturation for 
2 min at 50°C, denaturation for 15 sec at 95°C and primer binding and elongation for 
1 min at 60°C. A dissociation curve was measured in the range of 60°C to 95°C. Standard 
curves were template dilutions of cDNA generated from Universal Human Reference RNA 
(Agilent Technologies) and allowed to determine PCR efficiency and exact quantification 
of template. Results were normalized to house keeper genes HPRT and PGK.  
2.15. MassARRAY 
MassARRAY allows the quantification of DNA methylation of DNA fragments ranging from 
250 to 750 bp using mass spectrometry.321 For this method DNA is treated with bisulfite 
which results in the conversion of unmethylated cytosine to uracil, while methylated 
cytosine is protected from the reaction (Figure 10). The converted DNA is used as 
template for PCR amplification of the region of interest. In the PCR amplification, a T7 
promoter-tagged reverse primer is incorporated into the product which is necessary for in 
vitro transcription in the next step. The forward primer contains a 10 bp long sequence tag 
which balances PCR primer length. After in vitro transcription, products are applied to U-
specific cleavage resulting in a mix of smaller fragments which includes also fragments 
with one or more CpGs which are referred to as CpG units (CGUs). After purification all 
fragments are applied to MALDI-TOF MS analysis. Each CpG can result in a mass shift of 
16 kD of methylated in comparison to unmethylated DNA as the fragment either contains 
a guanine or an adenine. 
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Figure 10. MassARRAY methylation analysis. (A) Bisulfite conversion, PCR amplification, in vitro 
transcription and U-specific cleavage results in the preparation of small DNA fragments which vary in their size 
depending on the original DNA methylation status. (B) Mass spectrometry analysis is used for quantification of 
unmethylated and methylated CpG units. 
In this project, for MassARRAY analysis 0.5 to 1 µg of genomic DNA was bisulfite 
converted using either the EpiTectFast Bisulfite or the EpiTect Bisulfite conversion Kit 
(Qiagen) as described in the manual. DNA was eluted with buffer EB or DNase free water 
and 1-2 µl used for PCR amplification.  
10 µl PCR reactions were assembled with 0.1 µl HotStarTaq DNA Polymerase, 1 µl 
10xPCR buffer, 0.2 µl 25 mM MgCl2 (Qiagen), 1 µl 5 mM TMAC (Sigma-Aldrich), 0.8 µl 
2.5 µM dNTP mix (Roche) as well as 0.5 µl forward and reverse primer (10 µM). H2O was 
added to obtain a final volume of 10 µl. Samples were amplified on an Eppendorf PCR 
Cycler (Eppendorf) for 40 cycles as follows: initial denaturation and protein activation for 
15 min at 95°C, denaturation at 95°C for 60 sec, primer annealing at 60°C for 30 sec, 
elongation at 72°C for 1 min and final elongation at 72°C for 5 min. 5 µl of the PCR 
products were analyzed on 1.5% agarose gels. 
Subsequently, PCR products were processed with the reagents from the MassCLEAVE kit 
(Sequenom) as described by the manufacturer. To dephosphorylate any remaining, 
unincorporated dNTPs, PCR products were treated with shrimp alkaline phosphatase 
(SAP). A mix of 1.7 µl H2O and 0.3 µl SAP was added to 5 µl PCR product and incubated 
for 20 to 40 min at 37°C. Reactions were heat inactivated for 5 min at 85°C and stored on 
4°C or -20°C. For in vitro transcription and subsequent cleavage a T cleavage 
transcription RNase A cocktail was assembled which was added to 2 µl of the SAP 
reaction. Per reaction the cocktail contained 3.21 µl H2O, 0.89 µl 5x T7 polymerase buffer, 
0.22 µl T Cleavage Mix, 0.22 µl DTT (100 mM), 0.4 µl T7 RNA&DNA Polymerase and 
0.06 µl RNase A. Samples were incubated for 3h at 37°C and after addition of 20 µl H2O 
and 6 mg Clean Resin rotated on room temperature for 15 min. After centrifugation for 
5 min at 4000 rpm, samples were spotted onto Spectro Chips II with the MassARRAY 
Nanodispenser (Sequenom) and analyzed with the MassARRAY Analyzer 4 System 
(Sequenom).  
As controls 0% and 100% methylated DNA were processed together with the patient 
samples. For the 100% methylated control, CpG Methylated Human Genomic DNA 
(Thermo Scientific) was purchased or highly methylated DNA was generated in vitro. To 
do so 2.5 µg cell line DNA was treated with 0.5 µl CpG Methyltransferase (M.SSsI, NEB) 
in a 20 µl reaction including 2 µl 10x NEB buffer 2 and 0.25 µl 200x SAM at 37°C over 
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night. 2h after start of incubation 0.25 µl 200x SAM were added and 4h after start of 
incubation 0.25 µl 200x SAM and 0.35 µl M.SssI were added. For the 0% methylated 
control, 10 ng cell line DNA was applied to whole genome amplification using the REPLI-g 
Mini Kit (Qiagen) as described in the manual. 0% and 100% controls were purified using 
the QIAquick PCR purification kit (Qiagen) and 1 µg each applied to the MassARRAY 
protocol as described above.  
2.16. Cloning of pcDNA3.1-KLF4 
For cloning of pcDNA3.1-KLF4, KLF4 cDNA was amplified from whole transcriptome 
cDNA synthesized from MEC1 RNA as described in II.2.13. For PCR amplification 10 ng 
cDNA were used in 50 µl reactions containing 10 µl 5x HiFi Buffer, 0.5 µl 25 mM dNTP 
mix (Roche), 2 µl forward and reverse primer (10 µM), 1 µl PRECISOR High-Fidelity DNA 
Polymerase (Biocat) and H2O. Amplification was performed for 30 cycles on a Eppendorf 
PCR Cycler (Eppendorf) including the following steps: initial denaturation for 2 min at 
98°C, denaturation for 30 sec at 98°C, primer annealing at 55°C for 30 sec, elongation for 
2 min at 72°C and final extension at 72°C for 7 min. Primers used in this reaction 
contained tags with NotI and HindIII restriction sites. The PCR product was analyzed on a 
1% agarose gel and purified using QIAquick PCR purification kit (Qiagen). Subsequently, 
2 µg PCR product as well as 2 µg of the original plasmid (pcDNA3.1/V5-His, Life 
Technologies) were digested with NotI and HindIII FastDigest restriction enzymes for 1h 
at 37°C in 20 µl reactions containing 1 µl of each enzyme, 2 µl 10x FastDigest Buffer (Life 
Technologies) and H2O. Digestion products were separated on a 1.5% agarose gel and 
digested PCR fragment and empty vector backbone isolated with the QIAquick Gel 
extraction Kit (Qiagen). Of the PCR product and plasmid each 5 µl were assembled 
together with 8 µl H2O, 1 µl T4 DNA Ligase and 1 µl T4 DNA Ligase buffer (Life 
Technologies) and incubated for 5 min at room temperature. Of the ligation reaction 5 µl 
were used for the transformation of chemical competent OneShot Top10 E.coli (Life 
technologies) as described by the manufacturer and plated on LB-agar plates containing 
100 µg/ml ampicillin (Roche). After incubation over night at 37°C, colonies were used for 
inoculation of 5 ml LB-medium containing 100 µg/ml ampicillin (Roche) and again 
incubated over night at 37°C. Plasmids of these cultures were isolated and subsequent 
sanger sequencing used to check for plasmids with the right insert.  
Plasmid separation from E.coli was done with Plasmid Mini Kit and EndoFree Plasmid 
Maxi Kit (Qiagen) as described in the manual. Plasmids were applied to sanger 
sequencing to control insert identity and sequence.  
2.17. Statistical analysis 
Expression and MCIp-arrays performed with material from CD19+ B-cells and CLL cells 
were analyzed by Manuela Zucknick, Natalia Becker und Clemens Phillipen. Array data 
were quantile normalized and analyzed with the limma package.322 For expression arrays 
genes with a |log2FC| ≥ 1 and adjusted p-value ≤ 0.05 were considered as differentially 
expressed. For Agilent MCIp-methylation arrays 500 bp windows containing at least two 
oligonucleotides were tested for differential methylation between CLL and healthy. 
Differential methylated regions (DMR) with a median |log2FC ≥ 0.5 (of all CpG containing 
oligonucleotides within the window) and p ≤ 0.05 were considered as differentially 
methylated. Overlapping 500 bp windows were merged to obtain maximal DMRs. Analysis 
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of correlation between methylation and expression was done by Clemens Phillipen. For all 
differential expressed genes that had respective hyper- or hypomethylated DMRs, 
expression values for each available oligonucleotide on the array per gene were tested 
against each oligonucleotide of the DMRs for significant correlation using Pearson rank 
statistic. Genes with a correlation coefficient r ≤ -0.47 and p ≤ 0.021 were considered to 
show significant negative correlation. Expression arrays performed of cell lines after KLF4 
overexpression were quantile normalized and analyzed using QIAGEN’s Ingenuity 
Pathway Analysis (IPA, Qiagen). 
Furthermore, Students paired t-test and Mann-Whitney rank sum test were used to test for 
significant difference between two groups as indicated for the single experiments. 
p-values ≤ 0.05 were considered significant. Correlations were calculated with Pearson or 
Spearman rank correlation. 
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3. Patient and healthy donor sample characteristics 
3.1. CD19+ CLL cells and B-cells used for array analysis 
  Gender Karyotype IGHV Age MCIp Expression CD5+/CD20+ (%) 
CLL1 male normal unmut 59 yes yes 99.9 
CLL2 male normal unmut 64 no yes 99.8 
CLL3 male normal mut 66 yes yes 99.4 
CLL4 female normal unmut 62 yes yes 99.8 
CLL5 male normal mut 61 yes yes 99.8 
CLL6 male normal mut 59 yes yes 99.8 
CLL7 female normal mut 65 yes yes 99.7 
CLL8 male 13q mut 67 yes yes 100.0 
CLL9 male 13q unmut 68 yes yes 99.9 
CLL10 male 13q unmut 70 yes yes 99.8 
CLL11 male 13q mut 70 yes yes 99.6 
CLL12 male 13q unmut 51 no yes 99.7 
CLL13 female 13q mut 74 yes yes 99.6 
CLL14 female 13q mut 76 yes yes 99.5 
CLL15 male 13q mut 50 yes yes 92.9 
H1 NA     NA yes yes 94.3 
H2 NA     NA no yes 97.8 
H3 NA     NA yes yes 97.8 
H4 NA     NA yes yes 93.8 
H5 NA     NA no yes NA 
H6 NA     NA no yes 99 
H7 NA     NA yes yes 96 
H8 male     60 yes yes 96 
H9 female     57 yes yes 95 
 
3.2. CD19+ CLL cells and B-cells for validation of methylation and 
expression with MassARRAY and qRT-PCR 
CLL (n=56) B-cells (n=23) 
Gender female n=18 n=7 
male n=38 n=15 
NA - n=1 
Karyotype normal n=20 - 
13q14 deletion n=36 - 
Treatment untreated n=44 - 
 
treatment >12 
months before 
sampling point 
n=12 - 
IGHV status mutated n=30 - 
Unmutated n=25 - 
NA n=1 - 
Median age  62 56 
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3.3. PBMCs used for GSI-I treatment 
Frozen material n=8   
CD5+/CD19+ cells 91.6-98.8% 
Gender male n=1 
female n=7 
Karyotype 13q deletion n=7 
 
13q, 14q 
deletion n=1 
IGHV status mutated n=4 
unmutated n=4 
Age 45-78 
Treatment untreated n=8 
 
Fresh material n=4   
CD5+/CD19+ 47.4-68.8% 
Gender male n=2 
female n=2 
Karyotype 13q deletion n=3 
13q, 11q deletion n=1 
IGHV status mutated n=3 
unmutated n=1 
Age 26-76 
Treatment untreated n=4 
 
3.4. CLL1 clinical trial 
Prognostic factors and risk-adapted therapy in patients with early stage chronic 
lymphocytic leukemia323 
Design Prospective, open-label, multicenter, risk stratified phase III trial 
Objectives 
The CLL1-protocol uses a risk stratification strategy to identify a high risk 
(HR) and low risk (LR) group of early CLL patients. Patients are assigned to 
the HR arm by using the following definition:  
Elevated serum thymidine kinase (TK) >7,0 U/l or b2-microglobulin (b2-M) 
AND non-nodular bone marrow infiltration or short lymphocyte doubling time.
Afterwards the HR-patients are randomized to Fludarabine-therapy or "watch 
& wait 
Primary Endpoint Progression-free survival 
Secondary 
Endpoint(s) Overall survival, quality of life, incidence of infections 
Study Population B-CLL, Binet-Stage A, No pretreatment, Age ≥ 18 to ≤ 75 years 
Treatment F Arm: Fludarabine (25 mg/m2/d, d1-5) q28d; max 6 cycles Watch & Wait Arm: watch & wait 
Patients recruited 876 patients (198 pts. With high risk of progression) 
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3.5. CLL2H trial 
Subcutaneous Campath-1H (Alemtuzumab; MabCampath®) in Fludarabine-refractory 
CLL324 
Design Prospective, open-label, multicenter, phase II trial 
Objectives 
Has the subcutaneous administration of Alemtuzumab similar efficacy 
compared to intravenous administration, without the first-dose infusion-
related side effects? Can subcutaneous Alemtuzumab elicit responses in 
patients with high-risk genetic abnormalities (unmutated IgV H, del [17p], del 
[11q]) who have progressed on Fludarabine therapy? 
Study Population B-CLL, Binet-Stage C or A/B with need for treatment, F-refractory max 5 prior chemotherapies Age  ≥ 18 years 
Treatment 
Dose escalation: Alemtuzumab s.c. 3, 10, 30mg daily for 1-2 weeks  
+ Pegfilgrastim (Neulasta®) s.c. 6 mg forthrightly  
Therapy: Alemtuzumab s.c. 3x 30mg/week (d1+3+5), max 12 weeks  
--> SD or PD (optional): Alemtuzumab s.c. (max 12 weeks) + F (25 mg/m2) 
+ C (200 mg/m2), d1+3, q28d, max 3 cycles 
Patients recruited 109 patients 
 
3.6. CLL4 trial 
Fludarabine versus Fludarabine plus cyclophosphamide in first line therapy of younger 
patients (up to 65 years) with advanced chronic lymphocytic leukemia (CLL)325 
Design Prospective, open-label, multicenter, phase III trial 
Primary 
Endpoint(s) 
Rate of remission, duration of remission, progression-free survival (PFS), 
overall survival 
Secondary 
Endpoint(s) Incidence of side effects, quality of life 
Study Population 
B-CLL, Binet-Stage C or B/A with need for treatment 
No pretreatment 
Age  ≥ 18 to ≤ 65 years 
Treatment 
Arm F: 
Fludarabine (25 mg/m2/d, d1-5); q28d; max 6 cycles 
Arm FC: 
Fludarabine (25 mg/m2/d, d1-3) +Cyclophosphamide (250 mg/m2/d, d1-3); 
q28d; max 6 cycles 
Patients recruited 375 patients (F-Arm: 189, FC-Arm: 186) 
 
3.7. CLL8 trial 
Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and 
Rituximab (FCR) versus chemotherapy with Fludarabine and Cyclophosphamide (FC) alone 
in patients with previously untreated chronic lymphocytic leukaemia326 
Design Prospective, open-label, multicenter, 2-arm, randomized phase III trial 
Primary 
Endpoint(s) Progression-free survival (PFS) 
Secondary 
Endpoint(s) 
Event-free survival (EFS), overall survival, disease-free survival, duration 
of remission, time to new CLL or death, rates of molecular, complete and 
partial remission, response rates and survival times in biological 
subgroups, rates of treatment-related adverse effects, pharmacoeconomic 
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impact, quality of life 
Study Population 
B-CLL, Binet-Stage C or B with need for treatment 
No pretreatment 
Age  ≥ 18 years 
Treatment 
Arm FCR immunochemotherapy: 
Rituximab (Cycle 1: 375 mg/m2, d0;Cycles 2-6: 500 mg/m2, d1) 
+Fludarabine (25 mg/m2/d, d1-3) +Cyclophosphamide (250 mg/m2/d, d1-
3); q28d; max 6 cycles 
Arm FC chemotherapy: 
Fludarabine (25 mg/m2/d, d1-3) +Cyclophosphamide (250 mg/m2/d, d1-3); 
q28d; max 6 cycles 
Patients recruited 817 patients (FCR: 408, FC: 409) 
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III. Results 
1. Methylation- and expression array analysis reveals genes potentially 
deregulated by DNA methylation in CLL 
CLL is a disease of the epigenome known to show genome-wide hypomethylation and 
region specific hypermethylation that is able to influence gene expression. To find genes 
potentially deregulated by DNA methylation in CLL which might impact on disease 
pathogenesis, MCIp- and expression array analysis was performed.  
RNA and DNA of CD19+ CLL cells of 15 patients and B-cells from nine healthy donors 
were isolated and RNA applied to expression profiling on HumanHT-12v4 Illumina 
BeadChip Sentrix arrays. DNA was used for methyl-CpG-immunoprecipitation (MCIp) and 
the high salt fraction, containing highly methylated DNA, hybridized and analyzed on 
custom designed (eARRAY, Agilent) promoter arrays (2527020 G4125A Human custom 
CGH microarray 4x180K) covering -3.8 to +1.8 kb from the TSS of all human RefSeq 
genes. All CLL patients showed low risk disease with seven patients displaying normal 
karyotype and eight patients harboring 13q14 deletion at time of sampling. Patients had 
either unmutated (n=6) or mutated (n=9) IGHV status and a median age of 65 (see II.3.1). 
None of the patients had been treated prior to this study. For normalization of the two 
color arrays, MCIp samples generated from DNA of a pool of healthy T-cells was used as 
control. Two of the patient samples and three of the healthy donor samples could not be 
applied to methylation analysis due to loss of material during MCIp preparation and 
labeling for array hybridization, respectively.  
 
 
Figure 11. Expression- and MCIp array analysis of CD19+ CLL and B-cells. (A) Top genes differentially 
expressed between CLL and healthy donor B-cells (“H”). Genes known to play a role in CLL pathogenesis 
from previous studies are marked in blue. New potential candidate gens marked in yellow. (B) Median MCIp 
array methylation values display a broader heterogeneity in CLL samples (y-axis) in comparison to healthy 
donor samples (“H”, x-axis). Lines represent the median, dashed lines represent 1st and 99th percentile. 
Sample preparation and MCIp arrays were performed by Angela Garding. Data analysis was done by Manuela 
Zucknick and Natalia Becker. 
Analysis of the gene expression data revealed 1,866 genes to be differentially expressed 
between CLL cells and normal B-cells with |log2FC| ≥ 1 and adjusted p-value ≤ 0.05 
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(Figure 11A). Among these were a number of genes known to be deregulated in CLL or 
important for CLL pathogenesis from previous studies. These included the oncogene 
TCL1 which can, like its interaction partner JUNB, induce CLL-like disease in mice.327,328 
In addition, the oncogene BCL-2 was previously shown to be up-regulated by DNA 
hypomethylation in CLL and is important for prevention of apoptosis in the cancer 
cells.264,329 Similarly up-regulated in this data set were NOTCH1, which is known to be 
deregulated and mutated in CLL, as well as STAT1 and STAT6, LEF-1, TLR7 and 
IGFBP4.330–333 STAT1 is a promising treatment target in CLL as JAK kinase inhibitors and 
Fludarabine were shown to induce apoptosis in CLL cells via the blockage of STAT1 
signaling. LEF-1 presumably acts as pro-survival factor in CLL and in addition, the high 
expression of LEF-1 also present in the preleukemic state of CLL, monoclonal B-cell 
lymphocytosis, suggests a role for this gene in early CLL leukemogenesis.334 Genes that 
are down-regulated in CLL include the NFκB target molecules IL6 and IL8, which are 
higher expressed upon BCR stimulation in ZAP70 expressing CLL cells, as well as EBF1, 
CD86 and ITGB2.229,234,335,336 
 
Figure 12. Genes potentially deregulated by DNA methylation in CLL. Methylation values of MCIp arrays 
for CLL and healthy donor samples (H) are displayed in blue and yellow on the left, expression values of same 
samples in green and red on the right. Pearson rank correlation coefficient is indicated in grey. Correlation 
analysis was done by Clemens Phillippen. 
In addition to quantile normalization, MCIp array data of CLL and normal B-cells were 
normalized to signals of the T-cell pool control resulting in median log2FC(red/green 
signal) values (Figure 12B). Of note, CLL samples displayed a greater heterogeneity in 
their methylation values than normal B-cells as demonstrated by the range of methylation 
values within the 1st and 99th percentile of the two groups (1st to 99th percentile of 
B-cells = -0.46 / 0.37, of CLL = -1.13 / 0.62). To define differentially methylated regions 
(DMRs) in CLL, all promoter regions represented on the tiling-arrays were screened for 
500 bp windows that contained at least two oligonucleotides with differential methylation 
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between cancer and normal. With this approach, 2,191 genes were identified that 
contained at least one aberrantly methylated window. 1,472 of these DMRs were 
hypomethylated in CLL and 719 hypermethylated with a median |log2FC| ≥ 0.5 and 
p ≤ 0.05. Out of all genes displaying aberrant expression and concurrent methylation, 33 
were identified to be potentially transcriptionally deregulated by DNA methylation in CLL 
with at least one oligonucleotide within the DMR showing a significant negative correlation 
with gene expression (Pearson correlation coefficient of -0.79 ≤ r ≤ -0.47 and p ≤ 0.021, 
Figure 12). 
2. Aberrant methylation and expression of KLF4 and LILRA4 was confirmed 
in a large patient subset 
To further validate aberrant DNA methylation, MassARRAY methylation profiling was 
performed. Specific regions are amplified from bisulfite converted DNA and applied to 
enzymatic digest resulting in fragments of different size which contain at least one CpG 
and are referred to as CpG units (CGU). CGUs are analyzed with mass spectrometry and 
absolute methylation values for each CGU can be obtained. MassArray analysis of 
regions covering or lying within the DMRs of the respective 33 genes (Figure 12) was 
performed in the same samples used for MCIp analysis and could confirm aberrant DNA 
methylation in at least one CGU of 17 of these genes (Figure 13A).  
 
 
Figure 13. Technical validation of methylation- and expression-array data. (A) Technical validation of 
methylation with MassARRAY. 17 out of 33 genes showed at least one significantly differentially methylated 
CGU. Methylation values from MassARRAY quantification for all significant CGUs (p ≤ 0.05) between CLL and 
healthy are shown. MassARRAY analysis was performed together with Angela Garding. (B) Validation of 
expression for KLF4 and LILRA4 with qRT-PCR in a bigger sample subset; p-values are indicated by asterisk: 
**≤0.01; Mann-Whitney U test was used to test for significance; lines indicate mean;  
Among these 17 genes were the leukocyte immunoglobulin-like receptor subfamily A 
member 4 (LILRA4, ILT7) and the krüppel-like factor 4 (KLF4) which are both potentially 
important for activation, maturation and signaling of B-cells and could hence play a role in 
CLL pathogenesis. 
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LILRA4 is a surface receptor so far only shown to be present on plasmacytoid dendritic 
cells (pDCs), where it is able to activate ITAM (immunoreceptor tyrosin-based activation 
motif) mediated signaling. The interaction of LILRA4 with its ligand BST2 (CD317) results 
in the activation of NFAT signaling, phosphorylation of Src family kinases and SYK and 
the inhibition of the production of IFN-α and TFN-α by pDCs.337–339 Of note, if present on 
CLL cells, LILRA4 could interact with the ITAM-containing BCR and hence activate BCR-
mediated signaling. Interestingly, a SNP detected in LILRA4 shows significant genotypic 
association with progression free survival in CLL and a CLL cell line generated by in vitro 
EBV infection also showed higher expression of LILRA4 in comparison to lymphoblastoid 
cell lines generated from normal B-cells.340,341  
Accordingly, as already described in the introduction (I.4.5), KLF4 is known to be 
important for B-cell development and differentiation and was shown to act as tumor 
suppressor in other cancers and B-cell malignancies. Besides that, the expression of 
KLF4 increases during B-cell maturation and is decreased upon B-cell activation 
suggesting a role of KLF4 in maintaining the activation status of B-cells.310,342  
To further validate the aberrant expression of LILRA4 and KLF4, mRNA levels were 
measured with qRT-PCR in CD19+ cells of a larger sample cohort of 56 CLL patients and 
23 age-matched healthy donor samples. Similar to patient samples used for initial array 
analysis, all patients showed a low risk karyotype with either 13q14 deletion (n=36) or 
normal chromosomal pattern. The median age of patients was 62, of healthy donors 56. 
All patients were untreated before samples were obtained for this study (n=44) or had 
received treatment earlier than 12 months before sampling point. Importantly, expression 
levels of KLF4 and LILRA4 as measured by qRT-PCR confirmed overexpression of 
LILRA4 and transcriptional down-regulation of KLF4 in CLL (Figure 13B).  
DNA methylation was quantified in all of the depicted samples using MassARRAY. For 
LILRA4 and KLF4 each, one amplicon (MA1) was analyzed lying within or overlapping the 
DMRs identified by MCIp array analysis (Figure 14A). Two additional amplicons (MA2 and 
MA3) within the LILRA4 promoter region were analyzed, which covered CpGs recently 
shown to be hypermethylated in CLL by 450K Illumina array analysis from Kulis and 
colleagues.271 Five out of ten CGUs analyzed within the KLF4 amplicon revealed 
significant hypermethylation in CLL (Figure 14B). The mean methylation values over all 
CGUs further correlated significantly with gene expression. KLF4 is therefore likely 
regulated by DNA methylation (Figure 14C). As mentioned before, KLF4 was shown to be 
silenced by hypermethylation in a number of cancers, however in these studies aberrant 
methylation was detected up-stream of the TSS. Interestingly, no aberrant methylation in 
this region was detected according to the MCIp array data presented here. Moreover, in a 
recent DNA methylation screen in a large subset of CLL patients performed by Kulis et al. 
no differential methylation of KLF4 was detected, presumably as the respective region 
within the KLF4 gene body is not covered by the 450K arrays used in this study. For 
LILRA4 all CGUs measured in all three MassARRAY amplicons showed hypomethylation 
of CLL cells in comparison to normal B-cells (Figure 14D). Similar to KLF4, correlation of 
mean methylation values of all CGUs per amplicon with expression, confirmed regulation 
of the transcriptional activity of LILRA4 by DNA methylation in CLL. In addition, analogous 
results obtained for all three MA amplicons indicate a substantial hypomethylation of the 
whole LILRA4 promoter region. 
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Figure 14. LILRA4 and KLF4 are deregulated by DNA methylation in CLL. (A) Schematic illustration of 
KLF4 (left) and LILRA4 (right). Positions of DMRs identified by MCIp array as well as MassARRAY (blue)- and 
qRT-PCR amplicons (green) are depicted. Black boxes display exons. (B) Results of 10 CGUs measured with 
MassARRAY in the KLF4 promoter are shown and confirm hypermethylation within this region. (C) Correlation 
of KLF4 expression and mean promoter methylation was detected. (D) MassARRAY results from three 
different amplicons within the LILRA4 promoter are shown. MA1 lies within the DMR identified by MCIp array. 
MA2 and MA3 represent DMRs identified by Kulis et al.271 (E) All three MAs show significant correlation of 
mean methylation values of all CGUs with LILRA4 expression. p-values are indicated by asterisk: * ≤0.05, 
**≤0.01, ***≤0.001, ns non-significant; lines represent mean; Mann-Whitney U test and Spearman rank 
correlation were used to test for significance. 
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3. DNA methylation of KLF4 and LILRA4 promoter regions show no 
differences in initial analysis of clinical trial cohorts 
DNA methylation in CLL can not only be used to classify CLL cells on a genome wide 
level and compare them to their non-malignant counter parts, but single DMRs can also 
help to improve risk stratification like it has been shown for methylation of the ZAP70 
promoter.261,271 To test if DNA methylation of LILRA4 and KLF4 promoter not only impacts 
on gene expression but also has prognostic impact, MassARRAY was applied to subsets 
of patient samples from four different clinical trials conducted by the German CLL study 
group (GCLLSG), namely CLL1 (n=38), CLL2H (n=25), CLL4 (n=34) and CLL8 (n=94).  
 
 
Figure 15. MassARRAY analysis of KLF4 and LILRA4 promoters in clinical trial cohorts. Methylation in 
the KLF4 promoter (MA1) (A) and in the LILRA4 promoter (MA3) (B were measured with MassARRAY in 
samples from four different clinical trials: CLL1, CLL2H, CLL4 and CLL8 (only for KLF4). No differences in 
DNA methylation could be detected in either of the regions. Mann-Whitney U test was used to test for 
significance; lines indicate mean values.  
Due to limited amount of material, only KLF4 amplicon MA1 could be measured in all four 
trial cohorts in almost all samples available. MA3 within the LILRA4 promoter region was 
only analyzed within CLL1, -2H and -4 trial samples (Figure 15). No differences in 
previously untreated patients with median to strong disease stage (Binet stage B and C; 
CLL4 and CLL8) and patients with low disease stage (Binet stage A; CLL1) or Fludarabine 
refractory patients (CLL2H) could be detected in DNA methylation in these regions. 
However, at time of this work, follow up data of the patients were not available yet, and 
impact on prognostic factors like progression free or overall survival still has to be 
determined. 
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Of note, the methylation patterns for all clinical trials in the two amplicons reflect the 
pattern which was detected in the patient subset used for validation (Figure 14). For KLF4 
CGUs 4 and 5 showed the highest mean methylation ranging around 40% and CGUs 9 
and 10 the lowest mean methylation between 10% and 15% in the patient samples. For 
LILRA4 all CGUs showed mean methylation values below 20%, except CGUs 4 and 5 
where the mean methylation ranged between 20% to 40% for all trial cohorts.  
4. KLF4 does not induce BCL-2 family-mediated apoptosis in leukemia cell 
lines 
Due to its involvement in B-cell development and maturation, the role of KLF4 in the 
pathomechanism of CLL was investigated. In NHL and cHL KLF4 was shown to act as 
tumor suppressor where promoter hypermethylation is associated with KLF4 silencing. 
Here, as well as in CML cells and in advanced epithelial ovarian cancer, it could be shown 
that KLF4 can induce apoptosis via up-regulation of BAK1 and down-regulation of the 
BCL-2/BAX ratio.313,317,343 As described in the introduction, BAX and BAK are pro-
apoptotic members of the BCL-2 family. They can form complexes in the mitochondria 
membrane which leads to the release of Cytochrome c and pro-apoptotic factors in the 
cells resulting in cell death. This effect is counteracted by BCL-2 which can bind to both 
proteins and block their complex formation. It is hence possible that the down-regulation 
of KLF4 in CLL cells results in the abrogation of BCL-2 inhibition as well as BAX and BAK 
activation. These could be involved in the mechanisms mediating the apoptotic defect of 
CLL cells (Figure 16).  
 
 
Figure 16. Potential regulation mechanism of BCL-2 family-dependent apoptosis by KLF4. (A) In 
healthy B-cells expression of KLF4 could ensure a proper apoptotic mechanism by activation of BAX and BAK 
and inhibition of BCL-2 which leads to apoptotic cell death. (B) The down-regulation of KLF4 could possibly 
interrupt the apoptotic mechanisms and contribute to the apoptotic defect of the CLL cells. 
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In addition, it was shown for several types of cancer that KLF4 can inhibit cell-cycle 
progression by repression (amongst others) of the cell cycler regulator cyclin D1 
(CCND1).303,315,344  
To investigate the transcriptional regulation of BAK, BAX, BCL-2 and CCND1 by KLF4 in 
CLL, the respective mRNA levels were measured in the cohort of CD19+ B-cells and CLL 
cells used for validation of expression and methylation in (III.3). In fact, all four genes 
showed differential expression between CLL cells and healthy donor samples with BAK 
and BAX being down-regulated and BCL-2 and CCND1 up-regulated (Figure 17A). 
Moreover, the expression of BAK and BAX showed weak but significant positive 
correlation with KLF4 expression, while CCND1 and BCL-2 displayed remote negative 
correlation. These results suggest that all four genes are KLF4 targets in CLL (Figure 
17B). 
 
Figure 17. Expression of BAK, BAX, BCL-2 and CCND1 in CD19+ CLL and B-cells. (A) Expression of 
BAK, BAX, BCL-2 and CCDN1 mRNA was measured with qRT-PCR and normalized to PGK and HPRT. BAK 
and BAX show up-regulation, BCL-2 and CCND1 down-regulation in CLL. (B) Expression of BAK and BAX 
shows positive, of BCL-2 and CCND1 negative correlation to KLF4 expression. Lines indicate mean; Mann-
Whitney U test and Spearman rank correlation were used to test for significance; p-values are indicated by 
asterisk: *≤0.05; **≤0.01; ***≤0.001 
In order to further support this hypothesis, KLF4 was transiently overexpressed in the CLL 
cell lines MEC1 and MEC2 as well as the mantle cell lymphoma (MCL) cell line JeKo-1. 
Cells were transfected by nucleofection with pcDNA3.1-KLF4 and pcDNA3.1/V5-His 
empty vector control and harvested 24h after transfection. Untreated cells and cells 
applied to electroporation without DNA (mock) were used as additional controls and three 
(MEC1 and JeKo-1) to four (MEC2) independent experiments were performed. After 24h, 
viability was assessed with Annexin-V / 7AAD flow cytometry and RNA applied to qRT-
PCR measurements of BAX, BAK, BCL-2 and CCND1. The overexpression of KLF4 on 
protein level was confirmed with western blot (Figure 18B). Of note, no differences in the 
amount of viable cells could be detected between the empty vector control and KLF4 
overexpression samples (Figure 18A). Furthermore, KLF4 did not impact on the 
expression of its downstream targets in neither of the cell lines (Figure 18C). 
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Figure 18. Impact of transient KLF4 overexpression on BAK, BAX, BCL-2 and CCND1 expression 
levels in leukemia cell lines. Cell lines MEC1, MEC2 and JeKo-1 were transfected with KLF4 expression 
plasmid. Results of three (MEC1 and JeKo-1) to four (MEC2) independent experiments are shown. 
(-) untreated control; “mock” nucleofection w/o DNA; “EV” empty vector; “KLF” KLF4 overexpression; 
(A) AnnV / 7AAD flow cytometry 24h after transfection. Percent viable cells (Ann-Vneg / 7AADneg) are depicted. 
No differences in viability could be observed between KLF4 overexpression and empty vector control. 
(B) Western blot confirms overexpression of KLF4 24h after transfection. (C) No differences in expression of 
BAK, BAX, BCL-2 and CCND1 were observed 24h after transfection in either of the cell lines. Expression 
values were normalized to mock control and PGK/HPRT. Error bars represent standard deviation; boxes 
represent mean; Paired t-test was used to test for significance; p-values are indicated by asterisk: *≤0.05; ns 
non-significant. 
5. Inhibition of NOTCH1 activity by γ-secretase inhibitor treatment induces 
the expression of KLF4 in cell lines and primary CLL cells 
As described earlier, the gene coding for the signaling transmembrane receptor NOTCH1 
is recurrently mutated in 6-12% of CLL cases.242 In addition, CLL cells show increased 
expression and activity of the NOTCH1 pathway in comparison to normal B-lymphocytes. 
In other cancers, KLF4 is one of the NOTCH1 downstream targets and is activated by 
NOTCH1 either by direct binding of the NICD to the promoter or repressed via the 
activation of HES1.282,284 To assess a potential relationship between NOTCH1 signaling 
and KLF4 expression in CLL, NOTCH1 mRNA levels were measured in the cohort of 
CD19+ CLL and B-cells mentioned before. Similar to results from the expression array 
data (Figure 12A), up-regulation of NOTCH1 levels in CLL could be confirmed in our 
patient subset. However, no correlation between KLF4 expression and NOTCH1 was 
detected (Figure 19A and B). 
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Figure 19. Expression of NOTCH1 in CD19+ CLL- and B-cells. (A) NOTCH1 expression levels were 
measured with qRT-PCR and normalized to HPRT and PGK. Overexpression of NOTCH1 in CLL was 
confirmed. (B) NOTCH1 mRNA levels did not show any correlation with KLF4 expression levels. Mann-
Whitney U test and Spearman rank correlation were used to test for significance; p-values are indicated by 
asterisk: **≤0.01; lines indicate means; ns non-significant;  
Nevertheless, to test whether NOTCH1 activity, independent of gene expression, impacts 
on the expression of KLF4 in CLL, peripheral blood mononuclear cells (PBMCs) of CLL 
patients and six different leukemia and lymphoblastoid cell lines were treated with 
γ-secretase inhibitor GSI-I. Upon ligand engagement and activation of NOTCH1, its 
intracellular domain (NICD) is cleaved by the protein γ-secretase and consequently free to 
translocate into the nucleus where it acts in complex with other proteins like CSL and 
MAML1 as transcription factor and activates its downstream targets.280,345,346 Inhibition by 
GSI-I abrogates the activation of NOTCH1 and hence its target genes. 
Frozen PBMCs of eight CLL patients, with a tumor load of at least 92% CD5+CD19+ 
B-cells, were treated with 2.5 µM and 5 µM GSI-I for 24h. Untreated cells and 0.0002% 
DMSO were the controls.347 Similarly, the lymphoblastoid cell lines LCL-FM and LCL-MM 
which represent normal B-cells and the leukemia cell lines MEC1, MEC2, GRANTA-519 
and JeKo-1 were treated with the same concentrations in three independent experiments.  
Cell viability was determined with the CellTiter-Glo cell viability assay for cell lines and 
with Annexin-V / 7AAD flow cytometry for CLL cells, after 24h. A significant, dose-
dependent reduction of the living cell population could be detected for all cell lines and 
PBMCs of CLL patients after 24h (Figure 20A). Effects on LCL-MM were less pronounced, 
which could be explained by strong cluster formation observed in cell culture. Western blot 
analysis affirmed inhibition of NOTCH1 activity with 2.5 µM and 5 µM GSI-I, as levels of 
NICD and full length NOTCH1 (NP) were reduced in cell lines and primary CLL cells 
(Figure 20B). Despite previous findings from Rosati et al. no accumulation of the 
transmembrane form of NOTCH1 (N-TM) could be detected, but a protein band of 
unknown identity appeared at about 200 kD.  
In order to confirm the efficiency of NOTCH1 inhibition by GSI-I treatment, the expression 
of NOXA, HES1 and CNND1 was measured with qRT-PCR in all cell lines and in addition 
of MCL1 in all CLL samples treated. HES1 and CCND1 are direct downstream targets of 
NOTCH1 signaling and were shown to be repressed upon NOTCH1 inhibition.281,296,348,349 
Furthermore, MCL-1 and NOXA, two more members of the BCL-2 protein family, were 
previously shown to be up-regulated by GSI-I treatment and are necessary for GSI 
induced apoptosis in CLL cells and other cell types.347,350  
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Figure 20. NOTCH1 inhibition with GSI-I in cell lines and frozen PBMCs from CLL patients. Cell lines 
MEC1, MEC2, JeKo-1, LCL-FM and LCL-MM (three independent experiments each) and PBMCs form eight 
CLL patients were treated with 2.5 µM and 5 µM GSI-I for 24h. Untreated cells and cells treated with 0.0002% 
DMSO were controls. (A) CellTiter-Glo viability assay and Ann-V / 7AAD flow cytometry were used to assess 
viability of cell lines and CLL cells. RFU and Ann-Vneg/7AADneg cells normalized to untreated control are 
shown. (B) Western blot for NOTCH1 and KLF4 confirmed inhibition of NOTCH1 activation and up-regulation 
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of KLF4 expression. Examples for one experiment per cell line and two CLL patients are shown. GAPDH was 
used as loading control. NP full length NOTCH1, N-TM NOTCH1 transmembrane form. (C)+(D) qRT-PCR 
measurement for the expression of NOXA, CCND1, KLF4, HES1 and MCL1 in cell lines (C) and PBMCs of 
CLL patients (D). Paired t-test was used to test for significance; Error bars represent standard deviation; p-
values are indicated by asterisk: *≤0.5, **≤0.01, ***≤0.001, ns non-significant; NA only 2 out of 3 experiments 
could be analyzed; boxes represent mean. 
In fact, NOXA displayed significant up-regulation in all cell lines and to lesser degree in 
CLL patient samples (Figure 20C and D). HES1 also showed up-regulation on mRNA 
level while MCL1 was down-regulated in CLL cells upon GSI-I treatment. CCND1 levels 
were down-regulated in a subset of cell lines including MEC1, GRANTA-519 and JeKo-1 
and CLL cells as expected, but increased in LCL-FM, LCL-MM and to lesser degree in 
MEC2. In summary, GSI-I treatment led to mixed effects on reported effector genes which 
might be due to the analysis of mRNA levels instead of protein levels as done in previous 
studies. Furthermore, GSI-I treatment was shown to result in inhibition of the proteasome 
and an increase of endoplasmatic reticulum (ER) stress in CLL cells.347 
However, a strong induction of KLF4 expression on mRNA and on protein level could be 
detected in cell lines and CLL samples (Figure 20B to D). This indicates that KLF4 is in 
fact a downstream target of NOTCH1 signaling in CLL and that NOTCH1 inhibition results 
in the transcriptional activation of KLF4 expression.  
The same experimental setup was applied to freshly isolated PBMCs of three CLL 
patients (47% to 70% CD5+CD19+ B-cells) which were less sensitive to GSI-I treatment as 
confirmed by Annexin-V / 7AAD staining. Western blot and qRT-PCR for downstream 
targets (Figure 21) also displayed diverse and less pronounced effects on target genes 
but also a slight increase of KLF4 on mRNA level. 
 
 
Figure 21. GSI-I treatment of freshly isolated PBMCs from CLL patients. PBMCs from three CLL patients 
were treated with 2.5 µM and 5 µM GSI-I for 24h. Untreated cells and cells treated with 0.0002% DMSO were 
the controls. (A) Ann-V / 7AAD flow cytometry show a drop of viability after 24h. Percent living cells 
normalized to untreated control are shown. (B) Western blot for NOTCH1 and KLF4 shows weak NOTCH1 
inhibition and minor up-regulation of KLF4. (C) mRNA levels for NOXA, CCND1, KLF4, HES1 and MCL1 were 
determined by qRT-PCR. Paired t-test was used to test for significance; Error bars represent standard 
deviation; p-values are indicated by asterisk: *≤0.5, ns non-significant; NA only 2 out of 3 experiments could 
be analyzed; boxes represent mean. 
6. Expression profiling after KLF4 overexpression reveals iNOS- and BCR 
signaling genes as downstream targets 
The previous experiments showed that overexpression of KLF4 does not result in the 
deregulation of its downstream targets BAX, BAK, BCL-2 and CCND1 in leukemia cell 
lines. Therefore, expression profiling after overexpression of KLF4 in MEC1, MEC2 and 
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JeKo-1 was conducted to identify direct targets of the transcription factor in leukemia. 
Cells were transfected with pcDNA3.1-KLF4 and pcDNA3.1/V5-His as empty vector 
control by nucleofection. RNA was isolated from cells harvested 3h and 10h after 
transfection and applied to expression profiling on HumanHT-12v4 Illumina BeadChip 
Sentrix arrays. Overexpression of KLF4 on protein level could be verified with western 
blot, already 3h after transfection (Figure 22A). However, scatter plots of quantile 
normalized expression values (log2(signal)) demonstrate only minor changes in the 
transcriptional profile after 3h in the cell lines (Figure 22B). In contrast, 10h after 
transfection, expression profiles of MEC1 and MEC2 displayed striking up-regulation of a 
set of genes, while in JeKo-1, only minor effects could be observed.  
 
Figure 22. Expression profiling in leukemia cell lines after KFL4 overexpression. MEC1, MEC2 and 
JeKo-1 were transfected with pcDNA3.1-KLF4 (“KLF4”) and pcDNA3.1/V5-His as empty vector control (“EV”). 
Samples taken 3h and 10h after transfection were applied to expression profiling. (A) Western blot for KLF4 
confirms overexpression already after 3h. (B) Scatterplots for expression values (log2(signal)) for all cell lines 
3h and 10h after transfection. (C) Ingenuity pathway analysis reveals top canonical pathways deregulated in 
MEC1 and/or MEC2 10h after transfection. Top 7 pathways for both cell lines are shown. Red line marks 
p-value of 0.01. 
Ingenuity pathway analysis was performed with genes showing a deregulation of 
|log2FC| ≥ 0.38 10h after transfection for MEC1 (n=1,218), MEC2 (n=1,245) and JeKo-1 
(n=705), in order to identify the impact of KLF4 expression on cellular mechanisms. In 
case of MEC1 and MEC2 cellular functions potentially affected by the deregulated genes 
include cell death and survival as well as proliferation, cell to cell signaling and interaction 
but also hematological system development and hematopoiesis (Supplemental tables 1 to 
3, V.1). Furthermore, KLF4 targeted genes that are involved in a number of canonical 
pathways important for B-cell development, homing and maintenance including BCR-
signaling, leukocyte extravasation, iNOS- (nitric oxide synthase) and PI3K-signaling 
(Figure 22C).  
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Figure 23. Genes of the BCR signaling pathway are deregulated upon KLF4 overexpression. MEC1 and 
MEC2 cells were transfected with pcDNA3.1-KLF4 and EV control. Expression profiling 10h after transfection 
revealed 32 out of 167 genes of BCR signaling to be up- or down-regulated in one or both of the cell lines. 
Major elements of BCR signaling are displayed. Genes up- or down-regulated are marked in orange and 
green, respectively with borders of symbols representing MEC1 and filling MEC2. 
In CLL, apoptosis resistance is associated with enhanced iNOS expression and NO 
release and it was suggested that TLR-7 signaling stimulates NFκB dependent activation 
of the NO pathway.351 Moreover, KLF4 was shown to interact with p65 to induce iNOS in 
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macrophages.352 In this study, KLF4 deregulated several components of NFκB signaling 
including p50, p52 and p60 subunits of NFκB complex as well as IKK kinase family 
(IKBKB) and NFKBIE which are involved in the activation of NFκB signaling important for 
B-cell development and function.353–355 These findings indicate that KLF4 might to some 
degree be involved in the apoptosis resistance mechanism of CLL cells via activation of 
iNOS signaling. Furthermore, a significant proportion of genes involved in BCR signaling 
became deregulated after KLF4 overexpression in MEC1 and MEC2, suggesting impact 
of the epigenetic inactivation of KLF4 on the BCR signaling pathway that is central to the 
pathomechanism of CLL. 
Ingenuity pathway analysis of genes deregulated in JeKo-1 did not reflect a strong overlap 
in the expression profiles with MEC1 and MEC2. Top canonical pathways which showed 
significant deregulation are mitochondrial dysfunction and oxidative phosphorylation. 
Presumably, this can be assigned to the general weak impact of KLF4 on the 
transcriptional profile of the cells which might be due to the lower expression of the protein 
after 3h and 10h. 
Of note, upon KLF4 overexpression NOTCH1 was upregulated in MEC1 and MEC2 
(log2FC=1.08 and 1.25) and to some degree in JeKo-1 (log2FC=0.31) indicating the 
transcriptional regulation of NOTCH1 by KLF4. 
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IV. Discussion 
1. Genome wide promoter methylation analysis and expression profiling 
reveals low correlation between DNA methylation and gene expression in 
CLL 
In CLL, global DNA methylation was shown to be relatively stable over time and 
comparable in resting and proliferative compartments.270 Therefore, DNA methylation has 
proven to be a stable clinical marker in oncology, to some degree more reliable than 
protein or mRNA levels.356 In CLL as well, DNA methylation was shown to be predictive 
for biological and prognostic subgroups. Even further, the methylation status of single 
promoter regions can impact on the expression of its downstream genes and on CLL 
survival, as has been shown for BCL-2 and ZAP70.261,264 However, in previous DNA 
methylation studies no thorough integration of gene expression data has been conducted 
to elucidate the impact of DNA methylation on the transcriptional profile of CLL cells. 
Moreover, recent work on the characterization of the methylome of CLL cells was 
performed with Illumina 450K methylation arrays which quantify DNA methylation at the 
majority of elements thought to be of functional relevance, however with reduced 
coverage.271 
Therefore, in this work, expression- and methylation-array profiling on custom designed 
promoter tiling-arrays, which densely cover the promoters of all RefSeq genes, was 
conducted in CD19+ B-cells of CLL patients and healthy donors. This integrative approach 
aimed at the identification of genes which are transcriptionally deregulated in CLL due to 
stable, aberrant DNA methylation in their promoter regions. Consequently, genes should 
be revealed with prognostic and functional impact on the malignant cells, which so far 
went unnoticed in CLL. The small patient cohort (n=15) used in this study represented low 
risk disease, displaying no deletions in 17p or 11q nor trisomy 12. Hence, the influence on 
gene expression of these prominent genetic aberrations could be ruled out. Furthermore, 
all patients were untreated at time of sampling, therefore representing original disease 
status that most likely did not evolve yet or undergo clonal evolution due to treatment. Of 
note, in this present study, CLL patient samples were compared to CD19+ B-cells of 
healthy donors, which were considered as the healthy counterpart of CLL until recently. 
However, the cell of origin of this B-cell leukemia is still under debate, and previous 
expression profiling suggests CD5+ B-cells as source of disease development. Based on 
DNA methylation profiling, others subdivide the CLL cells into three groups, which they 
assign to naïve B-cell like, intermediate and memory B-cell like states.229,271 Hence, a 
clear definition of the cell of CLL origin is still missing. However, many prominent markers 
and candidate genes were found by comparison to normal CD19+ B-cells and since then 
proven to be of functional relevance in CLL, e.g. BCL-2 and ZAP70, underlining the 
pertinence of this project.261,264 
Among the 1,866 genes which appeared to be up- or down-regulated in the CLL cells, 
were a number of genes previously shown to have aberrant expression in CLL and / or to 
be important for leukemogenesis. These were the oncogenes BCL-2 and TCL1, as well as 
a number of transcriptional regulators like LEF-1, JUNB, EBF1, STAT1 and STAT6. 
Further signaling molecules and surface receptors including CD86, TLR7, IGFBP4, 
ITGB2, IL6 and IL8 were identified in this screen as aberrantly expressed. These results 
support the validity of this expression data set.  
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DNA methylation values measured with MCIp array in the same patients displayed a 
greater heterogeneity in CLL cells, showing a broader distribution of methylation values in 
comparison to normal B-cells. This finding goes in line with results from other groups who 
found in general a lower intratumor heterogeneity in DNA methylation of CLL cells in 
comparison to normal B-cells but nevertheless strong locally disordered methylation in the 
malignant cells. This results in intersample methylome variation not present in the healthy 
counterpart.273,274 However, a more detailed analysis of the methylation data generated in 
this thesis, according to genome wide distribution of methylation or representation in CpG 
islands, CGI shores and shelves as well as enhancers was not done as the custom tiling-
arrays used here display promoter regions only. As mentioned in the introduction a 
thorough and detailed analysis of DNA methylation patterns in CLL was done by other 
groups already. 271,273,274,357 
To reveal differentially methylated regions in the CLL cells the present dataset was 
screened for 500 bp windows which showed aberrant methylation in at least two 
oligonucleotides. Out of the 1,472 DMRs defined with this approach, only about one third 
showed hypermethylation while two thirds showed hypomethylation. This confirmed that 
reduced methylation in comparison to normal cells in general is more abundant in cancer 
than increased DNA methylation. Combining the expression and methylation data, finally 
33 genes could be identified which showed significant negative correlation between the 
expression and the methylation status of at least one oligonucleotide of the respective 
DMR. Considering the high amount of about 19,000 protein coding genes in the human 
genome this number appears rather small.358 However, it is known from other studies that 
in general the genome wide correlation of DNA methylation with expression in CLL is 
relatively small and not only restricted to the promoter sites.271 Hence, many regulatory 
elements which could show aberrant methylation that impact on gene expression are not 
covered on the promoter arrays used in this project or might display positive rather than 
negative correlation to gene expression. 
2. LILRA4 and KLF4 are deregulated in CLL by DNA methylation 
To confirm the differential methylation detected within the promoter regions of the 33 
genes depicted above, technical validation was performed with methylation specific mass 
spectrometry (MassARRAY) in the same samples. 17 out of these genes demonstrated 
aberrant methylation also with this method (Figure 13A). MassARRAY is a highly 
quantitative method which is based on mass spectrometry measurements of methylated 
and unmethylated DNA fragments. MCIp in contrast relies on the physiological binding of 
an MBD-Fc fusion protein to methylated DNA. While only about half of the DMRs could be 
validated with MassARRAY, the combinatory results of both methods assure the presence 
of aberrant methylation in these promoter regions. 
Of these genes, LILRA4 and KLF4 were selected for further validation, as both could play 
roles in the maturation and activation of CLL cells. The overexpression of LILRA4 and the 
down-regulation of KLF4 in the leukemia cells could be confirmed in a large patient 
subset, as well as promoter-wide hypomethylation of LILRA4 and hypermethylation of a 
region within the gene-body of KLF4. Thus, it appears that in fact both genes could be 
transcriptionally deregulated in CLL by DNA methylation. Moreover, to test the prognostic 
impact of abnormal methylation in both genes, MassARRAY was performed with DNA 
samples from four different clinical trials conducted by the German CLL study group 
(GCCSG), namely CLL1, CLL2H, CLL4 and CLL8. No differences could be detected 
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within the two MA amplicons of KLF4 and LILRA4 which were investigated, reflecting 
homogenous methylation status of both genes within patients of different clinical stages. 
However, the effect on more elaborate prognostic factors like progression free or overall 
survival and treatment response still remains to be elucidated as soon as the respective 
clinical information is available. 
In contrast to gene-body hypermethylation of KLF4 detected in CLL, in other cancer 
entities including cervical cancer and B-cell malignancies like NHL and cHL KLF4 is 
repressed by promoter hypermethylation upstream of the TSS.314,317 This raises the 
question how the hypermethylation of KLF4 within a CGI but downstream of the TSS and 
within the gene-body impacts on the transcriptional activity of its promoter. In CLL, gene 
body methylation outside CGIs has been described to be positively correlated with gene 
expression. In contrast, gene body CpGs whose methylation showed negative correlation 
with expression were related to enhancers.271 In other tissues and cancers, intragenic 
DNA methylation was shown to result in alternative splicing or the definition of alternative 
TSS.118,119 Furthermore, besides DNA methylation, other epigenetic factors not 
investigated in this work like histone modifications or the binding of chromatin remodelers, 
could influence the transcriptional regulation of KLF4 as well. Taken together, the exact 
mechanism underlying the deregulation of KLF4 in CLL is not clear. Also, if the aberrant 
methylation of KLF4 detected here solely results in the down-regulation of its expression 
or also in the transcription of deviant splice variants thereof remains to be elucidated.  
Together with OCT4, SOX2 and c-MYC, the transcription factor KLF4 is not only able to 
induce pluripotent stem cells from human dermal fibroblast, but also to reprogram non-
terminally differentiated mouse B-cells to a pluripotent state. 301,359 Besides, KLF4 seems 
to be important for maintaining quiescence of hematopoietic cells, acts as regulator of B-
cell number and is involved in activation-induced B-cell proliferation.310,311,342 These 
findings indicate that KLF4 could be an interesting target in the course of CLL. Hence, 
despite the uncharacterized mechanism of deregulation of KLF4, the continued project 
was aimed to investigate the functional impact of its down-regulation in CLL cells. 
As described before, LILRA4 is able to induce ITAM mediated signaling and hence, if 
present, could activate the BCR signaling pathway in CLL cells. Of note, in previous work 
from Herishanu and colleagues, LILRA4 was included in a BCR signature based on 
expression profiling of IGHV mutated and unmutated CLL cells which were activated by in 
vitro IgM cross-linking.247 CLL cells are considered to be activated B-cells which are highly 
dependent on BCR signaling. However, the effects of BCR engagement are diverse 
depending on IGHV mutations status and presumably IgM and IgD density on the cells.360 
Hence, the impact of LILRA4 on BCR signaling could be of great interest, especially as 
the ligand of LILRA4 (BST2) is also present on B-cells and other cells after pre-exposure 
to IFN-I. Unfortunately, functional characterization of LILRA4 was not successful as no 
commercial antibody nor a custom designed antibody was able to detect LILRA4 on 
protein level (data not shown). Moreover, no overexpression of LILRA4 could be obtained 
by transient transfection in different cell lines.  
3. KLF4 is re-expressed by GSI-I treatment in CLL cells and leukemia cell 
lines suggesting regulation by NOTCH1 signaling 
In previous work, KLF4 was shown to be a down-stream target of NOTCH1 signaling 
which can either repress or activate its transcription. NOTCH1 is currently under 
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investigation in the course of CLL as it is frequently mutated and constitutively active in 
CLL cells in contrast to normal B-cells. Furthermore, JAGGED1-ligand increases CLL 
survival and NFκB activity in the cancer cells while apoptosis is induced after blockage of 
NOTCH1 receptors.242,296,297 The exact mechanism, how NOTCH1 signaling impacts on 
CLL cell survival and development is currently under investigation. Repression of KLF4 by 
NOTCH1 could be one potential trigger how NOTCH1 mutations and activity-defects are 
mediated and sequester effects on CLL cell activation.  
Although KLF4 RNA levels did not correlate with aberrant NOTCH1 expression in our 
sample subset, treatment of frozen PBMCs from eight CLL patients and six different 
lymphoblastoid and leukemia cell lines with GSI-I confirmed the re-expression of KLF4 on 
RNA and protein level. However, one has to keep in mind that the inhibition of γ-secretase 
is not absolutely specific for NOTCH1 inhibition as the protein targets a whole panel of 
receptors.361 In CLL, it was shown that GSI-I treatment results not just in apoptosis of the 
cells but also in the inhibition of the proteasome as well as ER stress which might be 
NOTCH1-dependent but could also reflect side effects of the treatment on other signaling 
pathways.347 This could also explain the divergent results concerning the NOTCH1 
downstream targets MCL-1 and HES1 and GSI-I responsive genes NOXA and CCND1 
which was measured with qRT-PCR here, while investigated on protein level by 
others.281,296,347 Nevertheless, γ-secretase inhibitors are a common tool for the inhibition of 
NOTCH1 and are widely used in literature. The most prominent effects of the GSIs seem 
to be mediated by NOTCH1 inhibition. This is supported by the finding that a high NOTCH 
pathway activity could predict response to GSI in glioma tumor-initiating cells, for 
example.362 Besides, regulation of KLF4 by NOTCH1 described in literature supports the 
assumption that the re-expression of KLF4 is mediated by NOTCH1 inhibition in the CLL 
cells.  
Furthermore, the effects detected upon treatment of PBMCs freshly isolated from patient 
samples and immediately exposed to treatment were less pronounced than in the viably 
frozen cells. GSI-I treatment showed less impact not only on apoptosis induction but also 
on the transcription of the responsive genes, including KLF4. Reduced inhibition of 
NOTCH1 activity in these cells was also confirmed by western blot. On the one hand, the 
tumor load of the fresh samples ranging between 47% to 70% CD5+CD19+ B-cells was 
reduced in comparison to the frozen samples (over 92% CD5+CD19+ B-cells). Hence, 
T-cells, macrophages and monocytes still present in the cell mixture might be less 
susceptible to the treatment, show different effects or support the CLL cell survival which 
could influence the read outs. On the other hand it is possible that the previously frozen 
and subsequently thawed cells are more sensitive to the treatment as they reflect stressed 
cells.  
The exact mechanism how NOTCH1 regulates the activity of the KLF4 promoter in CLL 
cells is not clear. In intestinal epithelium and T-cell ALL NOTCH1 inhibits KLF4 
transcription by activation of HES1 which directly binds to the KLF4 promoter 
about -0.5 kb upstream of the TSS and acts as repressor.282,283 Another NOTCH1 
responsive element (NRE) -151 bp upstream of KLF4 was defined, which mediates KLF4 
repression by a so far unknown but HES1-independent mechanism.363 In head and neck 
cancer cells, JAGGED1-induced NOTCH1 signaling activates KLF4 by direct binding of 
NICD/CSL to its promoter -1.5 kb upstream.284 Considering these findings, an indirect 
effect for example via HES1 rather than direct binding of NICD/CSL can be expected in 
CLL, where NOTCH1 inhibits KLF4 expression. However, besides the regulation by 
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NOTCH1 and HES1 the expression of KLF4 can be influenced by a number of other 
transcription factors like SP1, AP-1 and KLF4 itself.364 These findings indicate that the 
regulation of KLF4 underlies a complex interplay of TFs of which binding might be in 
addition, influenced by the epigenetic make-up of the promoter region.  
Conversely to the regulation of KLF4 by NOTCH1 signaling, it was shown that KLF4 can 
regulate the expression of NOTCH1 as well. In epithelial cells the overexpression of KLF4 
promotes the expression of NOTCH1, its ligand DLL4 and its downstream target HES1, 
which are all direct transcriptional targets of KLF4.285 In keratinocytes a similar effect on 
NOTCH1 after KLF4 overexpression was seen, however a reduction of NOTCH1 
transcription could only be induced by knock-down of KLF4 and in addition the 
transcription factor SP3 indicating a synergistic control of NOTCH1 by these proteins.287 
We detected the up-regulation of NOTCH1 on mRNA level after transient KLF4 
overexpression in MEC1 and MEC2 and to some degree in JeKo-1. This would indicate 
an activating function of KLF4 on NOTCH1 in the leukemia cell lines and hereafter a 
potential negative feedback mechanism. 
4. Overexpression of KLF4 results in the deregulation of genes involved in 
BCR- and PI3K-signaling in leukemia cell lines 
Next, to analyze the effects of KLF4 repression on the pathomechanism of CLL, several 
downstream targets were investigated. In other B-cell malignancies and cancer entities 
KLF4 was shown to induce apoptosis by changing the BCL-2/BAX ratio and by activating 
the expression of BAK.317 In addition, KLF4 can regulate cell cycle progression amongst 
other means by repression of CCND1.344 The aberrant expression in CLL and the weak 
but significant correlation with KLF4 expression of all four target genes might indicate 
functional relationship and a regulation by KLF4. However, the transient overexpression of 
KLF4 in the three leukemia cell lines MEC1, MEC2 and JeKo-1 did not impact on the 
transcriptional activity of these genes. Moreover, KLF4 did not act as inducer of apoptosis 
in these cells, as no decrease of cell viability in comparison to the control could be 
detected 24h after transfection.  
The activation and repression of KLF4 downstream targets was shown to be dependent to 
some degree on the interaction of KLF4 with other transcriptional regulators. For example, 
cooperatively with MEIS2 and PBX1, KLF4 activates E-cadherin and p15 promoters, 
which is however partly dependent on PBX1 binding sites adjacent to the KLF4 
consensus sequences.365 Furthermore, while acting as transcriptional repressor of TP53, 
KLF4 was shown to increase the DNA-binding affinity of p53 through the formation of a 
ternary complex on the DNA. This mechanism is again dependent on the presence of 
neighboring response elements for both proteins and can for example induce the 
transcription of p21.304,366 In macrophages KLF4 was shown to interact with the NFκB 
subunit p65 to cooperatively induce iNOS promoter activity.352 Besides, KLF4 is also 
suspected to compete with other proteins like SP1 for the same binding sites.367 In AML, a 
negative correlation between KLF4 and histone deacetylase 1 (HDAC1) was discovered 
and knockdown of the latter resulted in increased expression of KLF4. Simultaneously, 
both KLF4 and HDAC1 were shown to competitively bind to the KLF4 promoter, regulating 
its transcription.305 Alongside transcriptional regulation, KLF4 activity can be partly blocked 
by phosphorylation of the protein by ERK1/2 which results in reinforced degradation, for 
example triggering the suppression of ESC differentiation.302 In summary, the regulatory 
effects of KLF4 in a cell seem to be strongly dependent on the presence of co-regulatory 
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interaction partners and antagonists. Therefore, to verify the exact impact of KLF4 on 
target genes in CLL, overexpression of the transcription factor in primary CLL cells might 
be necessary. Unfortunately, these cells are hard to transfect and neither nucleofection 
with plasmids nor with in vitro produced KLF4 mRNA resulted in detectable expression of 
the protein in this work.  
Nevertheless, in order to find genes regulated by KLF4 in the cell line models used in this 
project, expression profiling was conducted with samples taken 3h and 10h after 
transfection of MEC1, MEC2 and JeKo-1 with KLF4 coding plasmid. Analysis of the 
respective data revealed only a small set of genes which are deregulated after 10h in 
MEC1 and MEC2, while almost no major effects could be detected in JeKo-1 or after 3h in 
any of the cell lines. Western blots for KLF4 in all three cell lines showed strong induction 
of its expression in MEC1 and MEC2 after 3h already, while protein levels were reduced 
at 10h and to even higher degree after 24h. This might be an effect of degradation and the 
high apoptosis rate of the cells at this time point. In JeKo-1 the dynamics of KLF4 
overexpression were different with low protein levels after 3h, which increased after 10h 
and also after 24h. This could explain the low changes in gene expression patterns seen 
in the expression array data for JeKo-1 in comparison to MEC1 and -2.  
To analyze the genes deregulated by KLF4 overexpression, Ingenuity pathway analysis 
was performed with the data obtained 10h after overexpression. As expected from 
previous analysis results for JeKo-1, ingenuity pathway analysis gave different results in 
comparison to MEC1 and MEC2 which showed strong overlap in potentially affected 
pathways and cellular functions. Among the canonical pathways affected by gene 
expression changes in MEC1 and MEC2 were several which are known to be important 
for CLL- and B-cells including iNOS-, PI3K- and BCR signaling. It was shown previously 
that KLF4 can act as mediator of pro-inflammatory signaling in macrophages, amongst 
others by interaction with p65 and induction of iNOS.352 However, to my knowledge, no 
studies have been conducted on the impact of KLF4 on B-cell signaling and the effect of 
deregulation of genes involved in these pathways is hard to predict. Although, most genes 
deregulated in BCR- and PI3K-signaling in MEC1 and MEC2 showed up-regulation like 
BTK, SYK and VAV1/2, some were also down-regulated like IKBKB in both cell lines or 
PIK3R1 in MEC1. Furthermore, not only transcriptional activity but also protein 
phosphorylation, degradation as well as input signals can influence signaling in the cells.  
In CLL, PI3K- and BCR-signaling are tightly related and were shown to play an important 
role in the pathomechanism as they are activated by the microenvironment over all in the 
lymph nodes and are a driving factor for CLL tumor-cell survival.247,368,369 Moreover, CLL 
cells are believed in general to represent highly activated B-cells with an immunological 
profile that resembles the one of antigen-experienced B-lymphocytes. Presumably due to 
their activation status, not all cells respond to BCR stimulation and further the effects of 
BCR engagement in vitro are conflicting, apparently depending on CD38 as well as IgD 
and IgM density, resulting either in apoptosis or proliferation of the CLL cells.360 Of note, a 
number of novel inhibitors including the BTK inhibitor Ibrutinib and the PI3Kδ inhibitor 
Idelalisib are in use in the clinics and show promising results, highlighting the importance 
of these pathways for CLL cell survival.370–372 In addition, it was shown that NOTCH1 
activity synergizes with BCR and CD40 signaling to enhance B-cell activation and hence, 
the suppression of KLF4 by DNA methylation and NOTCH1 might represent and support 
the highly activated state of the CLL cells.373 
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5. Future Perspectives 
In this project expression- and methylation-array profiling in CLL cells and B-cells of 
healthy donors was conducted to identify genes deregulated by DNA methylation in CLL 
which possibly play a role on the pathomechanism of this disease. However, DNA 
methylation is only one layer of the epigenetic landscape impacting on gene transcription. 
To further shed light on the epigenetic regulation of the transcriptional profile of CLL cells 
additional factors including histone modifications, histone variants, chromatin accessibility 
and chromatin remodelers like polycomb group proteins or CTCF could be investigated. 
To this end chromatin immunoprecipitation (ChIP) for the respective proteins and 
modifications could be performed followed by array- or NGS-analysis. 
In this work, the transcription and stem cell factor KLF4 was shown to be silenced by 
hypermethylation in CLL. The inhibition of NOTCH1 activity by GSI-I treatment resulted in 
the re-expression of KLF4 which led to the assumption that in fact KLF4 is transcriptionally 
regulated by NOTCH1 in CLL cells. However, y-secretase inhibition is not specific for 
NOTCH1 and hence to prove this point, NOTCH1 knock-down should be performed in cell 
lines and primary CLL cells to test the direct impact on KLF4 transcription. Another 
possibility would be to test the effect of NOTCH1 knock-down and overexpression on 
KLF4-promoter-luciferase constructs where firefly luciferase activity represents KLF4 
promoter activation. Using this approach, NOTCH1 responsive elements could be deleted 
or mutated to identify the effector element of NOTCH1 signaling on KLF4 expression. 
To find downstream targets of KLF4 in CLL, expression profiling was conducted upon 
transient KLF4 overexpression in 3 leukemia cell lines. A more elaborate approach would 
be to directly investigate binding of KLF4 to gene promoters by KLF4 ChIP-Seq analysis. 
This could be performed in cell lines or in primary cells with or without KLF4 
overexpression, depending on cell material needed for this method. Validation with qRT-
PCR would be required subsequently. These data could complement the expression array 
data and help to distinguish between direct KLF4 targets and secondary transcriptional 
effects. The overexpression of KLF4 did not induce apoptosis in the cell lines. However, 
KLF4 is also known as regulator of proliferation which was not investigated in this work. 
Hence, cell cycle analysis with flow cytometry should be performed after KLF4 
overexpression. Moreover, ingenuity analysis revealed genes involved in BCR signaling to 
be deregulated after KLF4 overexpression. The question remains whether these changes 
really impact on signaling and activation status of the CLL cells. To test this, signaling 
upon KLF4 overexpression and BCR stimulation could be measured for example by 
phosphor-specific flow cytometry which can be used to measure the phosophorylation 
state of several members of the BCR pathway like SYK, BTK, ZAP70, ERK1/2 and PLCγ 
in a time resolved manner. Unfortunately, all experiments involving the overexpression or 
knock-down of proteins in CLL cells and leukemia cell lines require the transfection via 
electroporation of the cells. This method induces apoptosis in a large proportion of cells 
and potentially impacts on signaling status and capacity.  
Finally, in this work CLL cells were compared to CD19+ B-cells of healthy donors. As the 
cell of origin in this leukemia is still under debate, comparison to other B-cell subsets 
could be beneficial and further help to define a potential role of KLF4 in CLL 
pathogenesis.  
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V. Appendix 
1. Supplemental tables 
Tables 1-3: Summary of ingenuity pathway analysis of top deregulated genes 10h after 
KLF4 overexpression (|log2FC| ≥ 0.38) for MEC1, MEC2 and JeKo-1 
MEC1 
Diseases and Disorders p-value #molecules 
Cancer 3.43E-11 - 1.74E-03 374 
Inflammatory Response 7.56E-11 - 1.73E-03 207 
Hematological Disease 1.51E-09 - 1.69E-03 107 
Immunological Disease 1.51E-09 - 1.69E-03 186 
Organismal Injury and Abnormalities 1.51E-09 - 1.43E-03 278 
Molecular and Cellular Functions     
Cellular Development 6.02E-14 - 1.73E-03 321 
Cellular Growth and Proliferation 6.02E-14 - 1.73E-03 347 
Cell Death and Survival 1.36E-12 - 1.62E-03 333 
Cell- To-Cell Signaling and Interaction 7.56E-11 - 1.38E-03 160 
Cellular Movement 7.82E-11 - 1.30E-03 220 
Physiological System Development and Function    
Hematological System Development and Function 6.02E-14 - 1.73E-03 224 
Hematopoiesis 1.17E-12 - 1.22E-03 124 
Lymphoid Tissue Structure and Development 8.99E-12 - 1.22E-03 90 
Tissue Morpholgoy 2.33E-11 - 1.38E-03 143 
Immunce Cell Trafficking 7.56E-11 - 1.73E-03 141 
Top Canonical Pathways p-value Ratio 
B Cell Receptor Signaling 4,34E-06 25/167 (0.15) 
Leukocyte Extravasation Signaling 6,72E-06 27/193 (0.14) 
iNOS Signaling 8,39E-05 10/43 (0.233) 
PI3K Signaling in B Lymphocytes 1,24E-04 18/123 (0.146) 
Fcy Receptor-mediated Phagocytosis in 
Macrophages and Monocytes 1,32E-04 15/92 (0.163 
 
MEC2 
Diseases and Disorders p-value #molecules 
Inflammatory Response 5.32E-10 - 2.60E-03 202 
Cancer  9.53E-10 - 2.24E-03 368 
Infectious Disease 4.25E-07 - 2.15E-03 162 
Respiratory Disease 4.25E-07 - 2.10E-03 76 
Organismal Injury and Abnormalities 5.78E-07 - 2.69E-03 265 
Molecular and Cellular Functions     
Cellular Movement 1.44E-15 - 2.69E-03 236 
Cell Death and Survival  1.72E-10 - 2.60E-03 307 
Cell-To-Cell Signaling and Interaction  5.32E-10 - 2.32E-03 251 
Cellular Growth and Proliferation  6.93E-10 - 2.69E-03 332 
Cellular Development  1.73E-09 - 2.69E-03 302 
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Physiological System Development and Function  
Immune Cell Trafficking  1.42E-13 - 2.69E-03 155 
Hematological System Development and Function 9.17E-13 - 2.44E-03 213 
Hematopoiesis  5.04E-08 - 2.30E-03 94 
Lymphoid Tissue Structure and Development 5.04E-08 - 1.53E-03 80 
Tissue Morphology  3.76E-07 - 2.44E-03 131 
Top Canonical Pathways p-value Ratio 
PI3K Signaling in B Lymphocytes 2,91E-04 17/123 (0.138) 
IL-8 Signaling 3,16E-04 22/183 (0.12) 
Tec Kinase Signaling 1,09E-03 18/150 (0.12) 
Leukocyte Extravasation Signaling 1,57E-03 21/193 (0.109) 
Virus Entry via Endocytic Pathways 2,69E-03 12/89 (0.135 
 
JeKo-1 
Diseases and Disorders p-value #molecules 
Dermatological Diseases and Conditions  7.66E-09 - 1.09E-02 68 
Antimicrobial Response  1.51E-08 - 8.60E-03 22 
Inflammatory Response  1.51E-08 - 1.13E-02 63 
Immunological Disease  7.42E-08 - 1.14E-02 83 
Infectious Disease 2.82E-07 - 9.02E-03 83 
Molecular and Cellular Functions     
Cellular Growth and Proliferation 2.12E-08 - 7.43E-03 168 
Cell Signaling 1.95E-07 - 1.12E-02 41 
Cell Death and Survival  8.16E-07 - 1.14E-02 154 
DNA Replication, Recombination, and Repair  3.05E-06 - 1.02E-02 47 
Cellular Development  4.90E-06 - 1.11E-02 151 
Physiological System Development and Function 
Connective Tissue Development and Function 7.40E-06 - 6.98E-03 57 
Tissue Development  7.40E-06 - 1.14E-02 78 
Hematological System Development and Function 1.35E-05 - 1.07E-02 70 
Embryonic Development  1.24E-04 - 1.14E-02 69 
Organ Development  1.24E-04 - 1.11E-02 35 
Top Canonical Pathways p-value Ratio 
Mitochondrial Dysfunction 2,98E-07 17/152 (0.112) 
Oxidative Phosphorylation 5,09E-07 13/92 (0.141) 
Interferon Signaling 1,56E-06 8/34 (0.235) 
Tumoricidal Function of Hepatic Natural Killer Cells 2,84E-04 5/24 (0.208) 
PDGF Signaling 7,03E-04 8/77 (0.104) 
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gemeinsamen korreli-korrelas und Wonderfulplots, all der Obstsalat (manchmal sogar mit 
Grießbrei) sowie final der Lettitor. Aber natürlich auch unsere tollen Urlaube, 
Wandertouren, Pizza-Nights, Feierabendbierchen und Ausflüge mit den beiden Mädels. 
Vielen Dank auch an Mama Wolf für die Verköstigung mit Kuchen, Bärlauchbutter, 
Marmelade, Zucchini… 
Bei meinen Mädels Tine, Elle, Sabrina, Susanne und Sonja bedanke ich mich für den 
Spaß im Labor und auch außerhalb. Vor allem die zahlreichen, sonntagnachmittäglichen 
BBQs inklusive unzähliger Flaschen Sekt haben mir über die stressigsten Zeiten geholfen. 
Außerdem danke ich allen unseren tollen TAs, Sybille, Petra, Frauke, Verena und 
Magdalena und allen anderen, die mir so oft mir Rat und Tat zur Seite standen.  
Steffi und Daniela, euch danke ich für eine jahrelange wunderbare Freundschaf, die vielen 
Telefonate und und und… 
Stefan, du warst die beste Entdeckung die ich in Heidelberg gemacht habe. Danke für 
deine Unterstützung in den letzten Monaten und dafür dass du meine Launen so tapfer 
ertragen hast!  
Und nicht zuletzt, von ganzem Herzen ein großes Dankeschön an meine Eltern und 
meine Geschwister Michael und Sabine. Während meinem gesamten Werdegang habt ihr 
mich immer auf ganzer Linie und bei all meinen Entscheidungen unterstützt. Ihr hattet 
immer ein offenes Ohr für meine Sorgen. Ohne euch wäre ich nie so weit gekommen. 
 
